[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 251
1. Vergara HF, Ortiz DA, Martínez BH, Mosiñoz RM, Arellano JA: [Hand reconstructive surgery secondary to giant cell tumor]. Acta Ortop Mex; 2010 Sep-Oct;24(5):345-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hand reconstructive surgery secondary to giant cell tumor].
  • [Transliterated title] Cirugía reconstructiva de mano secundario a tumor de células gigantes.
  • The giant cell tumor of the bone is a neoplastic low grade lesion that usually appears in the epiphyseal or metaphyseal region of the long bones.
  • The lesion is usually solitary and becomes symptomatic when a considerable proportion of the bone has been destroyed.
  • It is thought to represent approximately 19% of the benign bone tumors and 9% of all the primary bone tumors, according to a review by Schajowicz.
  • The treatment of the giant cell tumor is controversial and the literature is confusing.
  • The giant cell tumor is located mainly in the hand.
  • Its potential aggressiveness makes us consider it in the differential diagnosis of the tumor lesions affecting the hand.
  • The purpose of this research work is to describe our experience with the treatment of the giant cell tumor in three cases that presented as a lytic, expansive lesion affecting the bones of the hand.
  • They were treated with tumor resection and a bone graft to fill the defect.
  • [MeSH-major] Bone Neoplasms / surgery. Finger Phalanges. Giant Cell Tumor of Bone / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21246807.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


2. Yanagawa T, Watanabe H, Shinozaki T, Takagishi K: Curettage of benign bone tumors without grafts gives sufficient bone strength. Acta Orthop; 2009 Feb;80(1):9-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curettage of benign bone tumors without grafts gives sufficient bone strength.
  • BACKGROUND AND PURPOSE: The defect that results after curettage of a bone tumor is usually filled in the same way.
  • We report the outcome in patients with benign bone tumors that were treated with curettage but no filling.
  • PATIENTS AND METHODS: We retrospectively studied 78 patients (mean age at the time of operation was 27 (6-73) years, 44 men) who had had a benign bone tumor curetted with no filling of the defect.
  • The commonest tumor types were giant cell tumor of bone (27), fibrous dysplasia (13), enchondroma (9), and simple bone cyst (7).
  • Local recurrence occurred in 9 patients; 7 of them had a giant cell tumor.
  • INTERPRETATION: Routine filling of curetted bone lesions does not appear to be necessary from a mechanical point of view.
  • [MeSH-major] Bone Neoplasms / surgery. Curettage / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Cysts / surgery. Bone Remodeling / physiology. Follow-Up Studies. Giant Cell Tumor of Bone / surgery. Humans. Middle Aged. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Knee. 2002 Feb;9(1):73-5 [11830385.001]
  • [Cites] Acta Orthop. 2009 Feb;80(1):2-3 [19297784.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] J Orthop Sci. 2002;7(2):194-8 [11956979.001]
  • [Cites] J Hand Surg Br. 2002 Oct;27(5):446-51 [12367544.001]
  • [Cites] Biomaterials. 2003 Jul;24(16):2739-47 [12711520.001]
  • [Cites] Arch Orthop Trauma Surg. 2004 Jun;124(5):301-5 [15014954.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jul;86(5):719-25 [15274270.001]
  • [Cites] J Bone Joint Surg Am. 1981 Mar;63(3):367-75 [7204433.001]
  • [Cites] Clin Orthop Relat Res. 1985 Jan-Feb;(192):149-58 [3967417.001]
  • [Cites] Acta Orthop Scand. 1984 Dec;55(6):597-600 [6524324.001]
  • [Cites] Z Kinderchir. 1985 Aug;40(4):217-20 [3864319.001]
  • [Cites] J Bone Joint Surg Am. 1986 Feb;68(2):235-42 [3511063.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):45-58 [3514036.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Clin Orthop Relat Res. 1988 Jan;(226):299-310 [3335103.001]
  • [Cites] Arch Orthop Trauma Surg. 1989;108(5):296-9 [2675797.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):189-90 [2249528.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):212-3 [2249537.001]
  • [Cites] J Hand Surg Am. 1991 Jan;16(1):139-42 [1995672.001]
  • [Cites] Arch Orthop Trauma Surg. 1992;111(2):61-5 [1562425.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] Calcif Tissue Int. 1995 Jul;57(1):64-8 [7671168.001]
  • [Cites] Clin Orthop Relat Res. 1995 Dec;(321):245-50 [7497676.001]
  • [Cites] Arch Orthop Trauma Surg. 1996;115(1):45-8 [8775710.001]
  • [Cites] Clin Orthop Relat Res. 1999 Feb;(359):176-88 [10078141.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Acta Orthop Scand. 1999 Jun;70(3):308-15 [10429612.001]
  • [Cites] Biomaterials. 2007 Jan;28(3):400-4 [17010424.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):510-3 [16736145.001]
  • [Cites] Acta Orthop. 2008 Feb;79(1):86-93 [18283578.001]
  • [Cites] Acta Orthop. 2009 Feb;80(1):4-8 [19234881.001]
  • [CommentIn] Acta Orthop. 2009 Feb;80(1):2-3 [19297784.001]
  • (PMID = 19234882.001).
  • [ISSN] 1745-3682
  • [Journal-full-title] Acta orthopaedica
  • [ISO-abbreviation] Acta Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Other-IDs] NLM/ PMC2823236
  •  go-up   go-down


3. Forsyth RG, De Boeck G, Baelde JJ, Taminiau AH, Uyttendaele D, Roels H, Praet MM, Hogendoorn PC: CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone. J Bone Miner Res; 2009 Jan;24(1):70-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone.
  • Giant cell tumor of bone (GCTB) is a benign bone tumor with a shown clinical behavior of local recurrences and rare distant metastases.
  • GCTB is composed of uniformly distributed osteoclastic giant cells, thought to originate from the fusion of monocyte-macrophage lineage cells, in a background consisting of mononuclear rounded cells and spindle-shaped cells.
  • Several reports showed the specific expression of markers, such as CD14 on the mononuclear rounded cell population, however, lacking osteoclastic giant cells.
  • Nineteen GCTB tumor samples of 19 patients were studied.
  • The mononuclear rounded cell population was positive for RANK, CD51, CD14, and CD33.
  • The osteoclastic giant cell population expressed RANK and CD51, as well as CD33, but was consistently negative for CD14 expression.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD14 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Bone Neoplasms / metabolism. Giant Cell Tumors / metabolism. Osteoclasts / metabolism
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Integrin alphaV / biosynthesis. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Neoplasm Metastasis. Receptor Activator of Nuclear Factor-kappa B / biosynthesis. Sialic Acid Binding Ig-like Lectin 3

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18767926.001).
  • [ISSN] 1523-4681
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Integrin alphaV; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / Sialic Acid Binding Ig-like Lectin 3
  •  go-up   go-down


Advertisement
4. Dhillon MS, Prasad P: Multicentric giant cell tumour of bone. Acta Orthop Belg; 2007 Jun;73(3):289-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric giant cell tumour of bone.
  • Although giant cell tumour (GCT) is seen quite frequently, multicentric giant cell tumour (MCGCT) is a rare entity occurring in less than 1% of patients with GCT.
  • The pathogenesis of MCGCT is debated; various mechanisms have been postulated, including contiguous spread, iatrogenic tumour cell seeding, benign metastasis, malignant transformation and de novo formation.
  • [MeSH-major] Bone Neoplasms. Giant Cell Tumor of Bone
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715717.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 77
  •  go-up   go-down


5. Tarng YW, Yang SW, Hsu CJ: Surgical treatment of multifocal giant cell tumor of carpal bones with preservation of wrist function: case report. J Hand Surg Am; 2009 Feb;34(2):262-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of multifocal giant cell tumor of carpal bones with preservation of wrist function: case report.
  • We report a rare case of multifocal giant cell tumor of bone involving the trapezium, trapezoid, capitate, and scaphoid with soft tissue extension.
  • Following intralesional resection, an autogenous corticocancellous iliac crest bone graft was used to fill the resultant defect and preserve carpal height and radiocarpal motion.
  • [MeSH-major] Bone Neoplasms / surgery. Carpal Bones / surgery. Giant Cell Tumor of Bone / surgery. Ilium / transplantation

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135808.001).
  • [ISSN] 1531-6564
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Farzaneh AH, Pardis PM: Central giant cell granuloma and fibrous dysplasia occurring in the same jaw. Med Oral Patol Oral Cir Bucal; 2005;10 Suppl 2:E130-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central giant cell granuloma and fibrous dysplasia occurring in the same jaw.
  • Fibrous dysplasia (FD) is a developmental tumor like condition that is characterized by replacement of normal bone by an excessive proliferation of cellular fibrous connective tissue intermixed with irregular bony trabeculae.
  • Central giant cell granuloma (CGCG) is described as a benign lesion affecting the mandible and maxilla that consists of a massive fibrohistiocytic proliferation with numerous heavily hemosiderin-laden multinucleate-giant cells.
  • Our differential diagnosis was osteoma, osteoid osteoma and Fd.
  • The histological feature reveal Central giant cell granuloma fibrous dysplasia.
  • Central giant cell granuloma and fibrous dysplasia occurring in the same jaw is rarely reported in the literatures.
  • [MeSH-major] Fibrous Dysplasia, Monostotic / complications. Granuloma, Giant Cell / complications. Mandibular Diseases / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Osteoma / diagnosis. Osteoma, Osteoid / diagnosis

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15995572.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Jakobs M, Häupl T, Krenn V, Guenther R: [MMP- and FAP-mediated non-inflammation-related destruction of cartilage and bone in rheumatoid arthritis]. Z Rheumatol; 2009 Oct;68(8):683-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MMP- and FAP-mediated non-inflammation-related destruction of cartilage and bone in rheumatoid arthritis].
  • [Transliterated title] MMP- und FAP-vermittelte inflammationsunabhängige Destruktion von Knochen und Knorpel in der rheumatoiden Arthritis.
  • INTRODUCTION: Due to morphological similarities of high-grade synovitis in rheumatoid Arthritis (RA) and mesenchymal, semimalignant tumors and the hypothesis that RA progression is not only inflammation-related, but also determined by tumor-like mechanisms, a comparison was made between expression profiles of RA, giant cell tumor of bone (GCT) and normal synovium (ND).
  • The presence of FAP in RA and in stroma of a semimalignant tumor indicates tumor-like tissue destruction in chronic synovitis associated with RA.
  • [MeSH-major] Arthritis, Rheumatoid / immunology. Bone and Bones / immunology. Cartilage / immunology. Gelatinases / analysis. Matrix Metalloproteinases / analysis. Membrane Proteins / analysis. Receptors, CCR / analysis. Serine Endopeptidases / analysis

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):1009-19 [16508983.001]
  • [Cites] Arch Pharm Res. 2005 Nov;28(11):1257-62 [16350852.001]
  • [Cites] Clin Sci (Lond). 2005 Sep;109(3):227-41 [16104843.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11156-63 [16322266.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19441-4 [15809306.001]
  • [Cites] Pathol Res Pract. 2005;201(10 ):649-63 [16325507.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):657-72 [12209155.001]
  • [Cites] Z Rheumatol. 2008 Feb;67(1):17-22, 24 [18210133.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Cytokine. 2005 Jun 7;30(5):254-63 [15927850.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] Cancer Biol Ther. 2007 Nov;6(11):1691-9 [18032930.001]
  • [Cites] Arthritis Rheum. 1999 Apr;42(4):650-8 [10211878.001]
  • [Cites] Z Rheumatol. 2005 Jun;64(5):334-42 [15965818.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Feb;78(2):161-71 [8625558.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7366-77 [15326482.001]
  • [Cites] Brain Res. 1982 Mar 25;236(2):451-61 [6121610.001]
  • [Cites] Arthritis Res. 2000;2(5):361-7 [11094449.001]
  • [Cites] J Rheumatol. 2006 Aug;33(8):1523-9 [16881109.001]
  • [Cites] Drug Resist Updat. 2005 Feb-Apr;8(1-2):51-8 [15939342.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31240-8 [15985430.001]
  • [Cites] Histol Histopathol. 2001 Jan;16(1):297-307 [11193206.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9 [2402505.001]
  • [Cites] Arthritis Rheum. 2002 Jan;46(1):13-20 [11817584.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):5381-5 [11673556.001]
  • [Cites] Ann Rheum Dis. 1999 Nov;58(11):691-7 [10531073.001]
  • [Cites] Clin Chim Acta. 2008 Mar;389(1-2):61-6 [18155162.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1144-8 [8912822.001]
  • [Cites] Z Rheumatol. 2002 Aug;61(4):396-404 [12426845.001]
  • (PMID = 19593575.001).
  • [ISSN] 1435-1250
  • [Journal-full-title] Zeitschrift fur Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Membrane Proteins; 0 / Receptors, CCR; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


8. Sawyer JR, Goosen LS, Binz RL, Swanson CM, Nicholas RW: Evidence for telomeric fusions as a mechanism for recurring structural aberrations of chromosome 11 in giant cell tumor of bone. Cancer Genet Cytogenet; 2005 May;159(1):32-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for telomeric fusions as a mechanism for recurring structural aberrations of chromosome 11 in giant cell tumor of bone.
  • Giant cell tumor of bone (GCTB) is a benign but often aggressive tumor with a tendency toward local recurrence.
  • A third tumor with clonal tas of 11pter showed 2 additional subclones, one with ring chromosome 11 and the other with an extra copy of 1q.
  • To our knowledge, the 2 cases with del(11)(p11) represent the first report of a recurring structural chromosome aberration in GCTB.
  • [MeSH-major] Bone Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Giant Cell Tumors / genetics. Neoplasm Recurrence, Local / genetics. Telomere

  • Genetic Alliance. consumer health - Chromosome 11.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860354.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. McGough RL, Rutledge J, Lewis VO, Lin PP, Yasko AW: Impact severity of local recurrence in giant cell tumor of bone. Clin Orthop Relat Res; 2005 Sep;438:116-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact severity of local recurrence in giant cell tumor of bone.
  • We retrospectively reviewed 183 consecutive patients diagnosed with giant cell tumor at the three most common sites (distal femur, proximal tibia, and distal radius) to determine the pattern of local tumor recurrence and the impact severity of the recurrence on adjacent joint function.
  • The primary tumor was treated in all patients with intralesional excision of tumor by curettage.
  • Forty-five patients developed locally recurrent disease.
  • The intrainstitutional recurrences were salvaged by a repeat curettage (n = 12) or en bloc osteoarticular resection (n = 10) for bone recurrences and wide local excision for soft tissue recurrence (n = 1).
  • The prereferral recurrences were salvaged by a repeat curettage (n = 7) and en bloc osteoarticular resection (n = 15) for bone recurrences.
  • Incomplete initial surgery, a delay in diagnosis of the recurrence of greater than 6 months, and subchondral recurrence of tumor were contributing factors in the failure to salvage the joint.
  • Despite its benign histology, giant cell tumor of bone is an aggressive tumor that demands meticulous attention to surgical detail and close postoperative surveillance for successful local tumor control and durable, joint-preserving function.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / pathology. Neoplasm Recurrence, Local
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Evidence-Based Medicine. Female. Femur / pathology. Femur / radiography. Femur / surgery. Humans. Joints / physiopathology. Joints / surgery. Limb Salvage / methods. Male. Middle Aged. Radius / pathology. Radius / radiography. Radius / surgery. Retrospective Studies. Tibia / pathology. Tibia / radiography. Tibia / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16131879.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Lee MH, Kim NR, Ryu JA: Cyst-like solid tumors of the musculoskeletal system: an analysis of ultrasound findings. Skeletal Radiol; 2010 Oct;39(10):981-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-three masses were identified, of which initial interpretation on gray scale included cystic tumor which pathology revealed to be solid tumors.
  • RESULTS: Of 23 masses, there were 5 giant cell tumors of the tendon sheath, 4 schwannomas, 3 vascular leiomyomas, 2 benign fibrous histiocytomas, 2 dermatofibrosarcoma protuberans, 2 granular cell tumors, 1 dermatofibroma, 1 fibroma of the tendon sheath, 1 fibromatosis, 1 eccrine spiradenoma, and 1 granulation tissue.
  • Care should be given to these solid tumors that have a cystic appearance and even lack internal vascularity on color Doppler imaging to enhance diagnosis of cystic and solid masses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2008 Jun;190(6):1621-6 [18492916.001]
  • [Cites] AJR Am J Roentgenol. 2008 Sep;191(3):716-20 [18716098.001]
  • [Cites] J Ultrasound Med. 2007 Oct;26(10 ):1323-8; quiz 1330-1 [17901135.001]
  • [Cites] J Ultrasound Med. 2008 Feb;27(2):171-6; quiz 177-8 [18204007.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1449-53 [12704067.001]
  • [Cites] J Ultrasound Med. 2000 Dec;19(12 ):823-30 [11127006.001]
  • [Cites] Ultrasound Med Biol. 2008 Jan;34(1):12-21 [17900795.001]
  • [Cites] Skeletal Radiol. 2009 Jul;38(7):637-49 [18846371.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):100-5 [3543017.001]
  • [Cites] AJR Am J Roentgenol. 1998 Feb;170(2):459-63 [9456964.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):741-4 [14975979.001]
  • [Cites] J Clin Ultrasound. 1982 May-Jun;10(5):243-5 [6804531.001]
  • [Cites] Clin Orthop Relat Res. 2000 Nov;(380):191-8 [11064991.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1445-9 [12034614.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10 ):1017-22; quiz 1023-5 [14606556.001]
  • [Cites] Ultrasound Q. 2005 Dec;21(4):259-70 [16344730.001]
  • [Cites] Radiographics. 2006 May-Jun;26(3):745-63 [16702452.001]
  • [Cites] Radiology. 1994 Oct;193(1):259-62 [8090903.001]
  • [Cites] AJR Am J Roentgenol. 2004 Aug;183(2):337-9 [15269021.001]
  • (PMID = 20186412.001).
  • [ISSN] 1432-2161
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. May SA, Deavers MT, Resetkova E, Johnson D, Albarracin CT: Giant cell tumor of soft tissue arising in breast. Ann Diagn Pathol; 2007 Oct;11(5):345-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of soft tissue arising in breast.
  • Primary giant cell tumor of soft tissue (GCT-ST) arising in breast is exceedingly rare.
  • We report a case of a 60-year-old woman with a primary breast giant cell tumor that appeared histologically identical to giant cell tumor of bone and had a clinically malignant course.
  • Histopathological evaluation revealed a neoplasm composed of mononuclear cells admixed with osteoclast-like giant cells resembling giant cell tumor of bone.
  • These features were most consistent with GCT-ST, an uncommon neoplasm of low malignant potential.
  • This case demonstrates the difficulty of predicting clinical behavior of GCT-ST of breast on the basis of histological features and depth of tumor alone.
  • The distinction of this entity from other more common primary breast tumors with giant cell morphology is also emphasized.
  • [MeSH-major] Breast Neoplasms / pathology. Giant Cell Tumors / pathology. Soft Tissue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17870021.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Vimentin
  •  go-up   go-down


12. Gebre-Medhin S, Broberg K, Jonson T, Gorunova L, von Steyern FV, Brosjö O, Jin Y, Gisselsson D, Panagopoulos I, Mandahl N, Mertens F: Telomeric associations correlate with telomere length reduction and clonal chromosome aberrations in giant cell tumor of bone. Cytogenet Genome Res; 2009;124(2):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomeric associations correlate with telomere length reduction and clonal chromosome aberrations in giant cell tumor of bone.
  • Giant cell tumor of bone (GCTB) is characterized cytogenetically by frequent telomeric associations (tas).
  • Clonal aberrations were found to be restricted to the group with a high level of tas, and the same group showed a significantly larger reduction in telomere length in tumor cells compared to peripheral blood cells.
  • [MeSH-major] Chromosome Aberrations. Giant Cell Tumor of Bone / genetics. Telomere / metabolism

  • COS Scholar Universe. author profiles.
  • figshare. supplemental materials - Supporting Data and Materials for the article .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19420923.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / POT1 protein, human; 0 / TERF1 protein, human; 0 / TERF2 protein, human; 0 / Telomere-Binding Proteins; 0 / Telomeric Repeat Binding Protein 2; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


13. Wang J, Pei F, Tu C, Zhang H, Qiu X: Serum bone turnover markers in patients with primary bone tumors. Oncology; 2007;72(5-6):338-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum bone turnover markers in patients with primary bone tumors.
  • OBJECTIVES: It was the aim of this study to investigate parameters of bone turnover such as serum bone-specific alkaline phosphatase (BALP) and N-terminal midfragment of osteocalcin (N-MID), as well as serum C-terminal telopeptide of type I collagen (CTX) in patients with primary bone tumors and to investigate their validity in differentiating malignant from benign bone tumors.
  • METHODS: A total of 219 patients with primary bone tumors entered the study.
  • In each group, the patients were divided into several subgroups (osteosarcoma, benign bone tumors or tumor-like lesions, giant cell tumor, and other primary malignant bone tumors).
  • CONCLUSIONS: A high serum BALP level is valuable for the diagnosis of adult osteosarcoma, but its use in the development of a differential diagnosis in the teenage patients is not advised because serum BALP levels are also affected by age, pubertal stage and growth velocity.
  • Both serum N-MID and serum CTX are hardly useful in the differential diagnosis of primary bone tumors.
  • [MeSH-major] Alkaline Phosphatase / blood. Biomarkers, Tumor / blood. Bone Neoplasms / blood. Bone Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18187955.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Collagen Type I; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


14. Lim YW, Tan MH: Treatment of benign giant cell tumours of bone in Singapore. Ann Acad Med Singapore; 2005 Apr;34(3):235-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of benign giant cell tumours of bone in Singapore.
  • INTRODUCTION: Giant cell tumour (GCT) is a distinct neoplasm of undifferentiated cells.
  • The exact cell of origin is unknown.
  • The multinucleated giant cells present are formed from the fusion of mononuclear cells.
  • Giant cell tumour is more common in Southeast Asia than in the West.
  • MATERIALS AND METHODS: Sixteen patients with giant cell tumour were treated in the Singapore General Hospital from 1993 to 2001.
  • The tumours were divided into 3 groups.
  • The tumours were graded radiologically after the method of Campanacci et al.
  • All the recurrences had a Campanacci grade II or III tumour.
  • CONCLUSION: Currettage, high-speed burring with added phenol/liquid nitrogen treatment and cementation is a useful and safe method in the treatment of giant cell tumours.
  • Patients who have Campanacci grade I tumours have the highest chance of being disease-free after the first operation.
  • [MeSH-major] Bone Neoplasms / therapy. Giant Cell Tumor of Bone / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Cryotherapy. Disease-Free Survival. Female. Humans. Hydrogen Peroxide / therapeutic use. Male. Middle Aged. Phenol / therapeutic use. Retrospective Studies. Singapore / epidemiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. PHENOL .
  • Hazardous Substances Data Bank. SODIUM PHENOLATE .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902343.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 339NCG44TV / Phenol; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


15. Guo QC, Shen JN, Wang J, Huang G, Zou CY, Jin S, Yin JQ, Liao WM: [Analysis of the factors affecting the recurrence of giant cell tumor of bone]. Zhonghua Wai Ke Za Zhi; 2006 Jun 15;44(12):797-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the factors affecting the recurrence of giant cell tumor of bone].
  • OBJECTIVE: To analyze the clinical factors affecting the recurrence of giant cell tumors (GCT) of bone.
  • The two factors of surgery method and burst out of bone-envelope appearance were related with the recurrence.
  • [MeSH-major] Bone Neoplasms. Giant Cell Tumor of Bone. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889722.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


16. Li WX, Ye ZM, Yang DS, Tao HM, Lin N, Yang ZM: [Endoprosthetic reconstruction after wide resection of primary bone tumor around the knee]. Zhonghua Wai Ke Za Zhi; 2007 May 15;45(10):665-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoprosthetic reconstruction after wide resection of primary bone tumor around the knee].
  • OBJECTIVE: To evaluate the effect and complication of the endoprosthetic reconstruction after wide resection of primary bone tumor around the knee.
  • METHODS: The retrospective analysis was performed on 83 patients undergoing the prosthetic reconstruction after the resection of the primary tumor around the knee between December 1995 and December 2005.
  • All the diagnoses were pathologically confirmed (58 patients with osteosarcoma, 2 with osteosarcomatosis, 1 with parosteal osteosarcoma, 4 with malignant fibrous histiocytoma, 13 with giant cell tumor of bone, 1 with leiomyosarcoma, 2 with Ewing's sarcoma, 2 with chondrosarcoma).
  • After operation, the Musculoskeletal Tumor Society (MSTS) score was used to evaluate the recovery of their corresponding functions.
  • CONCLUSIONS: Taken together, the tumor prosthesis gives a satisfactory functional outcome after the tumor around the knee is removed with a lower incidence of complication.
  • [MeSH-major] Arthroplasty, Replacement, Knee / methods. Bone Neoplasms / surgery. Knee

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688816.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Singh S, Mak I, Power P, Cunningham M, Turcotte R, Ghert M: Gene transfection in primary stem-like cells of giant cell tumor of bone. Stem Cells Cloning; 2010;3:129-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene transfection in primary stem-like cells of giant cell tumor of bone.
  • The neoplastic stem-like stromal cell of giant cell tumor of bone (GCT) survives for multiple passages in primary culture with a stable phenotype, and exhibits multipotent characteristics.
  • The pathophysiology of this tumor has been studied through the primary culture of these cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Stem Cells Cloning. 2011;4:23. Cunnigham, Melissa [corrected to Cunningham, Melissa]
  • (PMID = 24198518.001).
  • [ISSN] 1178-6957
  • [Journal-full-title] Stem cells and cloning : advances and applications
  • [ISO-abbreviation] Stem Cells Cloning
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3781737
  • [Keywords] NOTNLM ; TWIST / gene / giant cell tumor / primary cells / transfection
  •  go-up   go-down


18. Kao HL, Chang WC, Lee CH, Lee HS, Huang GS: Missed brown tumors in a young adult with decreased bone density. South Med J; 2010 Apr;103(4):371-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Missed brown tumors in a young adult with decreased bone density.
  • Brown tumors, a benign osteolytic process, are most commonly caused by hyperparathyroidism.
  • Multiple bone involvement is relatively rare.
  • There are many similarities in the radiologic and histological features of brown tumors and giant cell tumors (GCTs) of bone.
  • Herein, the case of a 32-year-old man with multiple osteolytic lesions of the left tibia and fibula as well as the fourth metacarpal bone of the left hand, previously misdiagnosed with multiple GCTs, is presented.
  • Based on the radiographic findings and biochemistry results in a young adult patient, brown tumor was suspected and subsequently definitively diagnosed.
  • [MeSH-major] Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / diagnosis. Hyperparathyroidism, Primary / diagnosis. Osteitis Fibrosa Cystica / diagnosis. Parathyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Bone Diseases, Metabolic / etiology. Diagnosis, Differential. Diagnostic Errors. Fibula / pathology. Humans. Hypercalcemia / etiology. Male. Osteolysis / diagnosis. Osteolysis / pathology. Parathyroid Hormone / blood. Parathyroidectomy. Tibia / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20224492.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone
  •  go-up   go-down


19. Janes S, Cid J, Kaye P, Doran J: Pancreatic osteoclastoma: immunohistochemical evidence of a reactive histiomonocytic origin. ANZ J Surg; 2006 Mar;76(3):198-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic osteoclastoma: immunohistochemical evidence of a reactive histiomonocytic origin.
  • [MeSH-major] Giant Cell Tumor of Bone / metabolism. Osteoclasts / pathology. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16626367.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  •  go-up   go-down


20. Ng PK, Tsui SK, Lau CP, Wong CH, Wong WH, Huang L, Kumta SM: CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. J Cell Biochem; 2010 May 15;110(2):438-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression.
  • Giant cell tumor (GCT) of bone is an aggressive non-cancerous tumor, which consists of multi-nucleated osteoclast-like giant cells, stromal cells, and monocytes.
  • It is believed that stromal cells are the neoplastic component of this tumor.
  • Expression of the receptor activator of nuclear factor kappa B ligand (RANKL) in the stromal cells stimulates the monocytes to form giant multi-nucleated osteoclast-like cells, causing bone over-resorption at the tumor site.
  • Previously, our group has reported the up-regulation of RANKL in GCT of bone stromal cells, but the mechanism is unknown.
  • Using stromal cell culture of GCT obtained from patients, we demonstrated the up-regulation of the transcriptional activator CCAAT/enhancer binding protein beta (C/EBPbeta).
  • To conclude, our study has shown that C/EBPbeta is a RANKL promoter activator in stromal cells of GCT of bone and we have proposed a model in which C/EBPbeta plays an important role in the osteolytic characteristics and pathological causes of GCT of bone.
  • [MeSH-major] Bone Neoplasms / metabolism. CCAAT-Enhancer-Binding Protein-beta / metabolism. Gene Expression Regulation. Giant Cell Tumor of Bone / metabolism. RANK Ligand / genetics. Up-Regulation

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20225273.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-beta; 0 / CEBPB protein, human; 0 / DNA Primers; 0 / RANK Ligand; 0 / TNFSF11 protein, human
  •  go-up   go-down


21. Minami A, Iwasaki N, Nishida K, Motomiya M, Yamada K, Momma D: Giant-cell tumor of the distal ulna treated by wide resection and ulnar support reconstruction: a case report. Case Rep Med; 2010;2010:871278
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell tumor of the distal ulna treated by wide resection and ulnar support reconstruction: a case report.
  • Giant-cell tumor of bone occurred in the distal end of the ulna is extremely uncommon.
  • A 23-year-old male had a giant-cell tumor occurred in the distal end of the ulna.
  • After wide resection of the distal segment of the ulna including giant-cell tumor, ulnar components of the wrist joint were reconstructed with modified Sauvé-Kapandji procedure using the iliac bone graft, preserving the triangular fibrocartilage complex and ulnar collateral ligament in order to maintain ulnar support of the wrist, and the proximal stump of the resected ulna was stabilized by tenodesis using the extensor carpi ulnaris tendon.
  • Postoperative X-rays showed no abnormal findings including recurrence of the giant-cell tumor and ulnar translation of the entire carpus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Trauma. 1979 Apr;19(4):219-26 [439177.001]
  • [Cites] Hand Surg. 2009;14(1):15-21 [19598316.001]
  • [Cites] J Hand Surg Am. 1987 Mar;12(2):189-96 [3559068.001]
  • [Cites] J Hand Surg Am. 1987 Mar;12(2):202-4 [3559070.001]
  • [Cites] Ann Chir Main. 1986;5(3):181-93 [3813693.001]
  • [Cites] J Hand Surg Am. 1985 Nov;10(6 Pt 1):837-44 [4078266.001]
  • [Cites] Hand. 1983 Feb;15(1):70-2 [6852660.001]
  • [Cites] Scand J Plast Reconstr Surg. 1982;16(2):177-81 [7156902.001]
  • [Cites] J Hand Surg Am. 1995 Jul;20(4):602-8 [7594287.001]
  • [Cites] J Hand Surg Am. 1995 Mar;20(2):324-6 [7775778.001]
  • [Cites] J Hand Surg Am. 1998 Mar;23(2):222-8 [9556259.001]
  • [Cites] J Hand Surg Am. 2000 Nov;25(6):1080-4 [11119666.001]
  • [Cites] J Bone Joint Surg Am. 1952 Oct;34 A(4):893-900 [12990629.001]
  • [Cites] J Hand Surg Am. 2006 Mar;31(3):440-4 [16516739.001]
  • [Cites] Acta Orthop. 2006 Apr;77(2):290-7 [16752293.001]
  • [Cites] Hand Clin. 1987 Nov;3(4):563-83 [3320066.001]
  • (PMID = 20592994.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2892703
  •  go-up   go-down


22. Gruenwald N, Demos TC, Lomasney LM, Rapp T: The case. Giant-cell tumor. Orthopedics; 2006 Feb;29(2):94, 167-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The case. Giant-cell tumor.
  • Giant-cell tumor is a benign but locally aggressive primary bone tumor that requires surgical management.
  • Most giant-cell tumors initially are demonstrated on radiographs as distal, subarticular, geographic osteolytic lesions.
  • Abundant giant cells on histology are reactive secondary to a neoplastic fibroblast-like stromal cell.
  • Giant cells are present in many neoplastic and non-neoplastic bone lesions; therefore the diagnosis of giant-cell tumors requires correlation of clinical, imaging, and pathologic data to exclude other lesions that demonstrate a similar histologic pattern.
  • A small number of giant-cell tumors result in lung lesions, many of which have benign histology, can be treated by wedge resection, and do not affect long-term outcome.
  • [MeSH-major] Bone Neoplasms / radiography. Giant Cell Tumor of Bone / radiography. Knee

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485448.001).
  • [ISSN] 0147-7447
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Cribb GL, Cool P, Hill SO, Mangham DC: Distal tibial giant cell tumour treated with curettage and stabilisation with an Ilizarov frame. Foot Ankle Surg; 2009;15(1):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distal tibial giant cell tumour treated with curettage and stabilisation with an Ilizarov frame.
  • Imaging and biopsy confirmed this to be a giant cell tumour of bone.
  • After a prolonged course of rehabilitation he has excellent function and has returned to hill walking and there is no evidence of recurrence of the giant cell tumour.
  • [MeSH-major] Bone Neoplasms / surgery. Curettage. Giant Cell Tumor of Bone / surgery. Ilizarov Technique. Tibia

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218062.001).
  • [ISSN] 1460-9584
  • [Journal-full-title] Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons
  • [ISO-abbreviation] Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Ngan KW, Chuang WY, Yeh CJ: Soft tissue recurrence of sacral giant cell tumour of bone as an intra-abdominal mass: an unusual presentation. Pathology; 2008 Apr;40(3):312-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue recurrence of sacral giant cell tumour of bone as an intra-abdominal mass: an unusual presentation.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / secondary. Soft Tissue Neoplasms / secondary
  • [MeSH-minor] Abdomen / pathology. Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Ovarian Neoplasms / pathology. Sacrum / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18428057.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


25. Muramatsu K, Ihara K, Taguchi T: Treatment of giant cell tumor of long bones: clinical outcome and reconstructive strategy for lower and upper limbs. Orthopedics; 2009 Jul;32(7):491
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of giant cell tumor of long bones: clinical outcome and reconstructive strategy for lower and upper limbs.
  • Giant cell tumor of bone is a rare and unpredictable lesion.
  • Twenty-three consecutive cases of giant cell tumor of long bones were treated in 10 years.
  • The most common tumor sites were the proximal tibia (10 cases), distal femur (8), and distal radius (3).
  • Functional outcomes as evaluated by the Musculoskeletal Tumor Society measure were successful, with an average score of 26.6 points (range, 22-30 points).
  • For giant cell tumor of the upper limb or for young patients, biological reconstruction should be applied.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Lower Extremity / surgery. Reconstructive Surgical Procedures / methods. Upper Extremity / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19634852.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Turcotte RE: Giant cell tumor of bone. Orthop Clin North Am; 2006 Jan;37(1):35-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of bone.
  • Giant cell tumor is a common benign bone tumor that possesses specific features including location at the end of long bone, a strong tendency toward local recurrence, and the rare capacity to metastasize to the lungs.
  • Preferred treatment usually consists of extensive curettage and filling of the cavity with bone graft or cement.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / surgery. Fractures, Spontaneous / pathology. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Bone Transplantation / methods. Combined Modality Therapy. Curettage / methods. Female. Humans. Incidence. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Assessment. Sex Distribution. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16311110.001).
  • [ISSN] 0030-5898
  • [Journal-full-title] The Orthopedic clinics of North America
  • [ISO-abbreviation] Orthop. Clin. North Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


27. Saikia KC, Bhuyan SK, Saikia SP, Rongphar R, Jitesh P: Resection and arthrodesis of the knee joint for giant cell tumours of bone. J Orthop Surg (Hong Kong); 2010 Aug;18(2):208-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection and arthrodesis of the knee joint for giant cell tumours of bone.
  • PURPOSE: To evaluate functional outcomes and complications following resection and arthrodesis of the knee for giant cell tumours (GCTs) of bone, in comparison to treatment by endoprosthetic replacements reported elsewhere.
  • METHODS: 18 men and 14 women aged 18 to 40 (mean, 28) years underwent resection and arthrodesis of the knee for GCTs of bone involving the distal femur (n=17) and proximal tibia (n=15).
  • Cancellous bone grafts were placed transversely along the struts and circumferentially over the host-graft junctions.
  • The mean size of the tumours was 10x8x6 cm.
  • [MeSH-major] Arthrodesis / instrumentation. Bone Neoplasms / surgery. Bone Plates. Bone Transplantation / methods. Fibula / transplantation. Giant Cell Tumor of Bone / surgery. Knee Joint

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20808014.001).
  • [ISSN] 2309-4990
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Balke M, Hardes J: Denosumab: a breakthrough in treatment of giant-cell tumour of bone? Lancet Oncol; 2010 Mar;11(3):218-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denosumab: a breakthrough in treatment of giant-cell tumour of bone?
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Giant Cell Tumor of Bone / drug therapy. RANK Ligand / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet Oncol. 2010 Mar;11(3):275-80 [20149736.001]
  • (PMID = 20149737.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / RANK Ligand; 4EQZ6YO2HI / Denosumab
  •  go-up   go-down


29. Moser A, Hoffmann KM, Walch C, Sovinz P, Lackner H, Schwinger W, Benesch M, Fritz G, Urban C: Intracranial reparative giant cell granuloma secondary to cholesteatoma in a 15-year-old girl. J Pediatr Hematol Oncol; 2008 Dec;30(12):935-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial reparative giant cell granuloma secondary to cholesteatoma in a 15-year-old girl.
  • Imaging studies revealed an intracranial mass of the right temporal bone causing temporal lobe displacement.
  • A first biopsy led to the diagnosis of intracranial giant cell reparative granuloma (GCRG), a rare benign tumor of the bone or soft tissue that can show expansive growth.
  • Cholesteatoma should be considered as a trigger for intracranial GCRG growth, especially if adjacent to the temporal bone.
  • [MeSH-major] Bone Diseases / etiology. Cholesteatoma, Middle Ear / complications. Granuloma, Giant Cell / etiology. Temporal Bone

  • Genetic Alliance. consumer health - Cholesteatoma.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131785.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


30. Zhou H, Liu Z, Liu C, Ma Q, Liu X, Jiang L, Wei F: Cervical chordoma in childhood without typical vertebral bony destruction: case report and review of the literature. Spine (Phila Pa 1976); 2009 Jun 15;34(14):E493-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We present a giant cervical chordoma without typical vertebral bony destruction in an 11-year-old girl.
  • SUMMARY OF BACKGROUND DATA: Chordomas are rare malignant bone tumors that arise at both the cranial and the caudal ends of the axial skeleton, characteristically destroying the bone.
  • METHODS: Discussion on the patient's clinical, radiologic history, and histopathologic diagnosis of the resected tumor, with a review of the relevant background literature.
  • RESULTS: We report the first case of cervical chordoma in a child without typical vertebral bony destruction, the diagnosis of which was difficult to confirm before and after operation.
  • CONCLUSION: Giant notochordal rest and benign notochordal cell tumors (BNCTs) need to be recognized for differential diagnosis of this atypical chordoma.
  • A long-term follow-up might be necessary for the diagnosis of this nontypical patient.
  • [MeSH-major] Chordoma / diagnosis. Spinal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19525829.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 28
  •  go-up   go-down


31. Lang S: [Differential diagnosis of giant cell-rich lesions of bone]. Pathologe; 2008 Nov;29 Suppl 2:245-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis of giant cell-rich lesions of bone].
  • The diagnosis of giant cell-rich lesions of bone is often problematic even for the experienced pathologist.
  • The diagnostic key lies in multinucleated osteoclast-like giant cells and a mononuclear stroma.
  • From the histological picture alone it is often difficult to distinguish between individual entities such as conventional giant-cell tumor of bone, non-ossifying fibroma, giant-cell tumor in hyperparathyroidism or an aneurysmal bone cyst.
  • Furthermore, these lesions can be confused with malignant bone tumors such as giant cell-rich osteosarcoma.
  • X-ray is important for a correct diagnosis since some of these tumors show a typical anatomic location, while age of the patient is also an important factor.
  • In most cases diagnosis is made on the basis of intraoperative frozen-section, but even in this setting, due to the poor quality of the material, it is very difficult to make a correct diagnosis of giant cell-rich lesions without X-ray and clinical data.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / pathology
  • [MeSH-minor] Adolescent. Adult. Bone and Bones / pathology. Child. Connective Tissue / pathology. Diagnosis, Differential. Female. Frozen Sections. Humans. Male. Middle Aged. Osteoclasts / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathologe. 1996 Jan;17(1):1-5 [8685089.001]
  • (PMID = 18836722.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Nahal A, Ajlan A, Alcindor T, Turcotte R: Dedifferentiated giant cell tumour of bone in the form of low-grade fibroblastic osteogenic sarcoma: case report of a unique presentation with follow-up. Curr Oncol; 2010 Aug;17(4):71-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated giant cell tumour of bone in the form of low-grade fibroblastic osteogenic sarcoma: case report of a unique presentation with follow-up.
  • Giant cell tumour (GCT) of bone is a locally aggressive benign tumour.
  • It can, however, undergo dedifferentiation, either de novo or secondarily after local recurrence or radiation.
  • Whether spontaneously occurring or induced by previous irradiation, this malignant transformation is typically defined as a high-grade anaplastic sarcoma devoid of giant cells.
  • Here, we describe the first case of dedifferentiated GCT in the appearance of low-grade fibroblastic osteogenic sarcoma with distant bone metastases.
  • This disease progression occurred without previous irradiation.
  • We confirm the aggressive behaviour of this tumour despite the deceptively bland appearance of the malignant component.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2007 Dec;51(6):864-6 [18042075.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):1-14 [17197914.001]
  • [Cites] Cancer. 1962 Jul-Aug;15:653-90 [14450279.001]
  • [Cites] Skeletal Radiol. 1997 Apr;26(4):246-55 [9151375.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] Skeletal Radiol. 1995 Aug;24(6):409-16 [7481896.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):104-8 [11310196.001]
  • [Cites] Mod Pathol. 1989 Sep;2(5):541-6 [2554283.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] Cancer. 1979 Oct;44(4):1393-402 [227563.001]
  • [Cites] Cancer. 1970 May;25(5):1061-70 [4910256.001]
  • [Cites] Skeletal Radiol. 2004 Mar;33(3):169-75 [14749901.001]
  • [Cites] Cancer. 2003 May 15;97(10):2520-9 [12733152.001]
  • [Cites] Am J Surg Pathol. 1987 Jul;11(7):516-25 [2440324.001]
  • (PMID = 20697518.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2913833
  • [Keywords] NOTNLM ; Giant cell tumour / dedifferentiation / malignancy / osteogenic sarcoma
  •  go-up   go-down


33. Campbell K, Wodajo F: Case report: two-step malignant transformation of a liposclerosing myxofibrous tumor of bone. Clin Orthop Relat Res; 2008 Nov;466(11):2873-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: two-step malignant transformation of a liposclerosing myxofibrous tumor of bone.
  • We present the case of a patient with malignant transformation of a liposclerosing myxofibrous tumor.
  • The patient had a histologically confirmed liposclerosing myxofibrous tumor that, during a course of 22 months, spontaneously transformed into a lesion appearing like a benign giant cell reactive lesion and subsequently into a high-grade bone sarcoma.
  • Few such cases of spontaneous malignant transformation of liposclerosing myxofibrous tumor have been reported.
  • We report what we believe to be the first case documenting spontaneous transformation of a liposclerosing myxofibrous tumor into an intermediate lesion with benign-appearing histologic features and then into a high-grade malignant tumor.
  • [MeSH-major] Femoral Neoplasms / diagnosis. Fibroma / diagnosis. Lipoma / diagnosis. Liposarcoma, Myxoid / diagnosis. Myxoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Femur / pathology. Femur / radiography. Follow-Up Studies. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):21-7 [16788939.001]
  • [Cites] Radiology. 1999 Sep;212(3):693-8 [10478234.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):104-8 [11310196.001]
  • [Cites] J Bone Miner Res. 2006 Dec;21(12):1955-8 [17002568.001]
  • [Cites] Pathol Int. 2003 Jan;53(1):46-50 [12558870.001]
  • [Cites] Skeletal Radiol. 2003 Mar;32(3):143-6 [12605278.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1204-9 [14652823.001]
  • [Cites] Indian J Pathol Microbiol. 2003 Apr;46(2):215-7 [15022914.001]
  • [Cites] Radiographics. 2004 Sep-Oct;24(5):1433-66 [15371618.001]
  • [Cites] Histopathology. 2004 Oct;45(4):369-76 [15469475.001]
  • [Cites] Mayo Clin Proc. 1981 May;56(5):294-306 [6939953.001]
  • [Cites] Clin Orthop Relat Res. 1988 Mar;(228):281-9 [3277758.001]
  • [Cites] Skeletal Radiol. 1990;19(5):347-52 [2165632.001]
  • [Cites] Bull Hosp Jt Dis Orthop Inst. 1990 Fall;50(2):169-76 [2175663.001]
  • [Cites] Hum Pathol. 1993 May;24(5):505-12 [8491490.001]
  • [Cites] Hum Pathol. 1993 Nov;24(11):1264 [8244329.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):750-5 [8077356.001]
  • [Cites] J Orthop Res. 1996 Mar;14(2):311-5 [8648511.001]
  • [Cites] J Bone Joint Surg Am. 1997 Feb;79(2):259-62 [9052550.001]
  • [Cites] Skeletal Radiol. 1997 Apr;26(4):246-55 [9151375.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Rheumatology (Oxford). 2001 Jun;40(6):706-7 [11426034.001]
  • (PMID = 18607664.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2565027
  •  go-up   go-down


34. Qi ZH, Li CF, Ma XX, Li ZF, Zhang K, Yu DX: [Changes of 3-tesla 31P-MR spectroscopy of bone and soft tissue tumors]. Zhonghua Zhong Liu Za Zhi; 2009 Jun;31(6):442-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes of 3-tesla 31P-MR spectroscopy of bone and soft tissue tumors].
  • OBJECTIVE: To study the characteristic changes of 31P-MR spectroscopy of bone and soft tissue tumors.
  • METHODS: 41 patients were examined by phosphorus surface coil of 3 tesla MR machine, including 18 benign tumor foci and 28 malignant foci, and adjacent normal muscles.
  • RESULTS: The ratios of Pcr/PME and PME/NTP in benign and malignant tumor groups were significantly different from those of the normal group (P<0.05).
  • Between benign and malignant tumor groups, the ratios of PME/beta-ATP and PME/NTP were significantly different (P<0.05).
  • CONCLUSION: Pcr/PME and PME/NTP are potential diagnostic indexes of bone and soft tissue tumors.
  • PME/beta-ATP and PME/NTP are potential indexes of differential diagnosis of bone and soft tissue tumors.
  • [MeSH-major] Bone Neoplasms / diagnosis. Giant Cell Tumors / diagnosis. Magnetic Resonance Spectroscopy / methods. Osteosarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adenosine Triphosphate / metabolism. Adolescent. Adult. Aged. Child. Diagnosis, Differential. Female. Fibroma / diagnosis. Fibroma / metabolism. Humans. Male. Middle Aged. Organophosphates / metabolism. Phosphocreatine / metabolism. Phosphorus / metabolism. Phosphorus Isotopes. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / metabolism. Young Adult


35. Panasiuk M, Iwański A: Diagnostic difficulties in pigmented villonodular synovitis. Presentation of cases. Ortop Traumatol Rehabil; 2008 Nov-Dec;10(6):613-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the literature, this condition has been called xanthoma, xanthogranuloma, villous arthritis, pigmented villonodular synovitis, xanthomatous giant cell tumour, giant cell tumour of tendon sheath, giant cell fibrohemangioma, benign synovioma.
  • The paper presents two cases in which, due to ignorance of this disease, patients were primarily qualified for oncological treatment: chemotherapy and radical resection or limb amputation.
  • [MeSH-major] Synovitis, Pigmented Villonodular / diagnosis. Synovitis, Pigmented Villonodular / surgery
  • [MeSH-minor] Adolescent. Ankle Joint. Diagnosis, Differential. Female. Giant Cell Tumor of Bone / diagnosis. Hemangioma / diagnosis. Humans. Knee Joint / blood supply. Magnetic Resonance Imaging. Middle Aged. Synovial Membrane / surgery. Terminology as Topic

  • Genetic Alliance. consumer health - Pigmented villonodular synovitis.
  • Genetic Alliance. consumer health - Synovitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153550.001).
  • [ISSN] 1509-3492
  • [Journal-full-title] Ortopedia, traumatologia, rehabilitacja
  • [ISO-abbreviation] Ortop Traumatol Rehabil
  • [Language] eng; pol
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


36. Malek F, Krueger P, Hatmi ZN, Malayeri AA, Faezipour H, O'Donnell RJ: Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy. Int Orthop; 2006 Dec;30(6):495-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy.
  • Giant cell tumour (GCT) is a benign, but aggressive, primary tumour of the bone.
  • Many surgical techniques have been employed in the treatment of this tumour.
  • In addition to curettage, various adjuvant procedures and packing materials have been advocated in order to control and reconstruct long bone defects secondary to this neoplasm.
  • We report our experience with 40 long bone GCT patients treated with curettage, burring, bone grafting and no adjuvants between 1997 and 2002.
  • The risk of local recurrence in this study is acceptable (within the range that has been historically reported for curettage and bone grafting).
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation / methods. Giant Cell Tumor of Bone / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cohort Studies. Developing Countries. Female. Humans. Iran. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):259-70 [11953617.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • [Cites] Recent Results Cancer Res. 1976;(54):257-61 [1013500.001]
  • [Cites] J Bone Joint Surg Am. 1980;62(4):652-6 [7380862.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):755-61 [7045129.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):206 [2249534.001]
  • [Cites] J Bone Joint Surg Am. 1993 Nov;75(11):1648-55 [8245057.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] Clin Orthop Relat Res. 1995 Dec;(321):245-50 [7497676.001]
  • [Cites] Bull Hosp Jt Dis. 1998;57(1):6-10 [9553696.001]
  • [Cites] Pathol Int. 1998 Sep;48(9):723-9 [9778111.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Bull Hosp Jt Dis. 1999;58(2):98-104 [10509202.001]
  • [Cites] Clin Orthop Relat Res. 2005 Jun;(435):211-8 [15930941.001]
  • [Cites] Clin Orthop Relat Res. 2005 Oct;439:144-50 [16205153.001]
  • [Cites] Clin Orthop Relat Res. 2002 Jul;(400):201-10 [12072763.001]
  • (PMID = 16896875.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3172751
  •  go-up   go-down


37. Baud'huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, Gouin F, Duplomb L, Heymann D: Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol; 2010 May;221(1):77-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis.
  • M-CSF, the main ligand for c-fms, is required for osteoclastogenesis and has been already identified as a critical contributor of the pathogenesis of giant cell tumours of bone (GCTs), tumours rich in osteoclasts.
  • In contrast to osteoblasts, bone-resorbing osteoclasts showed very strong staining for IL-34, suggesting its potential role in the pathogenesis of GCTs by facilitating osteoclast formation.
  • [MeSH-major] Bone Neoplasms / metabolism. Carcinoma, Giant Cell / metabolism. Interleukins / biosynthesis. Osteoclasts / cytology. RANK Ligand / physiology
  • [MeSH-minor] Adult. Aged. Animals. Anisoles / pharmacology. Antigens, CD11b / analysis. Bone Resorption / metabolism. Bone Resorption / pathology. Cell Adhesion / drug effects. Cell Proliferation / drug effects. Cell Survival / drug effects. Cells, Cultured. Dose-Response Relationship, Drug. Female. Humans. Male. Mice. Mice, Inbred C57BL. Middle Aged. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Neoplasm Proteins / pharmacology. Pyrimidines / pharmacology. Receptor, Macrophage Colony-Stimulating Factor / antagonists & inhibitors. Receptor, Macrophage Colony-Stimulating Factor / physiology. Signal Transduction / physiology. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 20191615.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine; 0 / Anisoles; 0 / Antigens, CD11b; 0 / Interleukins; 0 / Neoplasm Proteins; 0 / Pyrimidines; 0 / RANK Ligand; 0 / TNFSF11 protein, human; 0 / interleukin-34, human; EC 2.7.10.1 / Receptor, Macrophage Colony-Stimulating Factor
  •  go-up   go-down


38. Chadha M, Agarwal A, Wadhwa N: Chondroid chordoma of the L5 spinous process and lamina: a case report. Eur Spine J; 2005 Oct;14(8):803-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chordoma is a rare bone tumor that originates from the remnants of the notochord.
  • A differential diagnosis of a benign tumor (giant cell tumor, aneurysmal bone cyst or osteoblastoma) was made initially.
  • The tumor was removed enbloc.
  • Histopathological examination revealed the tumor mass to be chordoma.
  • [MeSH-major] Chordoma / pathology. Diagnosis, Differential. Lumbar Vertebrae / pathology

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spine (Phila Pa 1976). 2000 Oct 1;25(19):2537-40 [11013508.001]
  • [Cites] Spine (Phila Pa 1976). 2001 Jan 1;26(1):27-35 [11148642.001]
  • [Cites] J Neurosurg. 2001 Apr;94(2 Suppl):284-91 [11302633.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):756-61 [15166667.001]
  • [Cites] Eur Spine J. 1994;3(2):115-7 [7874548.001]
  • [Cites] Spine (Phila Pa 1976). 1996 Jul 1;21(13):1569-77 [8817786.001]
  • [Cites] Am J Clin Pathol. 1995 Mar;103(3):271-9 [7532910.001]
  • [Cites] Cancer. 1973 Aug;32(2):410-20 [4722921.001]
  • [Cites] Clin Oncol. 1984 Jun;10(2):167-72 [6734008.001]
  • [Cites] Skeletal Radiol. 1986;15(3):242-6 [3790204.001]
  • [Cites] Histopathology. 1987 Aug;11(8):775-87 [3305286.001]
  • [Cites] J Spinal Disord. 1989 Jun;2(2):69-74 [2520065.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):2943-9 [7693324.001]
  • [Cites] Spine (Phila Pa 1976). 1997 May 1;22(9):1036-44 [9152458.001]
  • (PMID = 15895260.001).
  • [ISSN] 0940-6719
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3489257
  •  go-up   go-down


39. Knowles HJ, Athanasou NA: Canonical and non-canonical pathways of osteoclast formation. Histol Histopathol; 2009 03;24(3):337-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Physiological and pathological bone resorption is mediated by osteoclasts, multinucleated cells which are formed by the fusion of monocyte / macrophage precursors.
  • Both canonical and non-canonical pathways of osteoclast formation play a role in the formation of osteolytic lesions where there is increased osteoclast formation and activity, such as in giant cell tumour of bone.
  • [MeSH-minor] Cytokines / metabolism. Humans. Macrophage Colony-Stimulating Factor / metabolism. Macrophage Colony-Stimulating Factor / physiology. Models, Biological. Osteolysis. RANK Ligand / metabolism. Receptor Activator of Nuclear Factor-kappa B / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130404.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Cytokines; 0 / RANK Ligand; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / Tumor Necrosis Factor-alpha; 81627-83-0 / Macrophage Colony-Stimulating Factor
  • [Number-of-references] 123
  •  go-up   go-down


40. Yu XC, Xu M, Song RX, Fu ZH, Liu XP: Long-term outcome of giant cell tumors of bone around the knee treated by en bloc resection of tumor and reconstruction with prosthesis. Orthop Surg; 2010 Aug;2(3):211-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of giant cell tumors of bone around the knee treated by en bloc resection of tumor and reconstruction with prosthesis.
  • OBJECTIVE: To study the long-term outcomes and complications of giant cell tumors around the knee treated with en bloc resection and reconstruction with prosthesis.
  • The affected limb functions were evaluated by the Musculoskeletal Tumor Society scoring system.
  • CONCLUSION: En bloc resection and reconstruction with prosthesis is a feasible method for treating giant cell tumor of bone around the knee.
  • [MeSH-major] Arthroplasty, Replacement, Knee. Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Knee Joint / surgery. Tibia / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Tianjin Hospital and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 22009951.001).
  • [ISSN] 1757-7861
  • [Journal-full-title] Orthopaedic surgery
  • [ISO-abbreviation] Orthop Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


41. Moskovszky L, Szuhai K, Krenács T, Hogendoorn PC, Szendroi M, Benassi MS, Kopper L, Füle T, Sápi Z: Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes Chromosomes Cancer; 2009 Jun;48(6):468-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis.
  • Genetic instability in relation to clinical behavior was studied in 52 cases of giant cell tumor of bone (GCTB).
  • Ploidy was determined in the mononuclear cell population by using native cell smears and image cytometry.
  • Genome-wide alterations were tested using array comparative genomic hybridization (array-CGH) on magnetically separated CD68-negative tumor cells.
  • Random individual-cell aneusomy was significantly (P < 0.001) more frequent in the recurrent groups (36.01 +/- 11.94%) than in the benign nonrecurrent cases (10.65 +/- 3.66%).
  • [MeSH-major] Bone Neoplasms / genetics. Genomic Instability. Giant Cell Tumor of Bone / genetics. Ploidies
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / genetics. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / genetics. Antigens, Differentiation, Myelomonocytic / metabolism. Centromere / metabolism. Chi-Square Distribution. Chromosomes, Human, Pair 11. Comparative Genomic Hybridization. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Telomere / genetics. Telomere / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. beta Catenin / genetics. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242928.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / CTNNB1 protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin
  •  go-up   go-down


42. Bhadani PP, Sah SP, Sen R, Singh RK: Diagnostic value of fine needle aspiration cytology in gouty tophi: a report of 7 cases. Acta Cytol; 2006 Jan-Feb;50(1):101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND The diagnosis of gout can be problematic when the presentation is atypical and serum uric acid is borderline elevated.
  • Demonstration of monosodium urate (MSU) crystals in fine needle aspiration (FNA) smears from nodular masses clinically suspected to be tophi establishes the diagnosis unequivocally.
  • Giant cell tumor of tendon sheath, giant cell tumor of bone and metastatic tumor with multicentric involvement of bone were the clinical diagnoses in 1 case each.
  • Bright field microscopy of FNA smears revealed singly scattered or stacks of MSU crystals with variable number of inflammatory cells, with or without foreign body giant cells in 6 cases.
  • [MeSH-major] Arthritis, Gouty / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Bone Neoplasms / diagnosis. Crystallization. Diagnosis, Differential. Giant Cell Tumors / diagnosis. Humans. Male. Microscopy, Polarization. Middle Aged. Neoplasm Metastasis. Soft Tissue Neoplasms / diagnosis. Tendons. Uric Acid / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514850.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 268B43MJ25 / Uric Acid
  •  go-up   go-down


43. Dickson BC, Li SQ, Wunder JS, Ferguson PC, Eslami B, Werier JA, Turcotte RE, Kandel RA: Giant cell tumor of bone express p63. Mod Pathol; 2008 Apr;21(4):369-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of bone express p63.
  • p63 contributes to skeletal development and tumor formation; however, little is known regarding its activity in the context of bone and soft tissue neoplasms.
  • The purpose of this study was to investigate p63 expression in giant cell tumor of bone and to determine whether it can be used to discriminate between other giant cell-rich tumors.
  • Seventeen cases of giant cell tumor of bone were examined to determine the cell type expressing p63 and identify the isoforms present.
  • Total RNA or cell protein was extracted from mononuclear- or giant cell-enriched fractions or intact giant cell tumor of bone and examined by RT-PCR or western blot, respectively.
  • Immunohistochemistry was used to evaluate p63 expression in paraffin embedded sections of giant cell tumor of bone and in tumors containing multinucleated giant cells, including: giant cell tumor of tendon sheath, pigmented villonodular synovitis, aneurysmal bone cyst, chondroblastoma, and central giant cell granuloma.
  • The mononuclear cell component in all cases of giant cell tumor of bone was found to express all forms of TAp63 (alpha, beta, and gamma), whereas only low levels of the TAp63 alpha and beta isoforms were detected in multinucleated cells; DeltaNp63 was not detected in these tumors.
  • Western blot analysis identified p63 protein as being predominately localized to mononuclear cells compared to giant cells.
  • This was confirmed by immunohistochemical staining of paraffin-embedded tumor sections, with expression identified in all cases of giant cell tumor of bone.
  • Only a proportion of cases of aneurysmal bone cyst and chondroblastoma showed p63 immunoreactivity whereas it was not detected in central giant cell granuloma, giant cell tumor of tendon sheath, or pigmented villonodular synovitis.
  • The differential expression of p63 in giant cell tumor of bone and central giant cell granuloma suggest that these two tumors may have a different pathogenesis.
  • Moreover, p63 may be a useful biomarker to differentiate giant cell tumor of bone from central giant cell granuloma and other giant cell-rich tumors, such as giant cell tumor of tendon sheath and pigmented villonodular synovitis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Neoplasms / metabolism. Giant Cell Tumor of Bone / metabolism. Membrane Proteins / biosynthesis
  • [MeSH-minor] Blotting, Western. Diagnosis, Differential. Gene Expression. Giant Cell Tumors / pathology. Granuloma, Giant Cell / pathology. Humans. Immunohistochemistry. Protein Isoforms / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311114.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Protein Isoforms
  •  go-up   go-down


44. Jarkiewicz-Kochman E, Gołebiowski M, Swiatkowski J, Pacholec E, Rajewski R: Tumours of the metatarsus. Ortop Traumatol Rehabil; 2007 May-Jun;9(3):319-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumours of the metatarsus.
  • BACKGROUND: Tumours of the metatarsus are rare and more frequently affect males.
  • Single cases of the following tumours have been discussed: giant cell tumour, metastases (lung, prostate gland), chondroblastoma, aneurysmal bone cyst, Ewing's sarcoma, clear cell carcinoma, osteosarcoma, intraosseous ganglion, chondromyxoid fibroma and granuloma.
  • We present our own clinical experience with metatarsal tumours during the period of the last 20 years.
  • The aim of the present study was to carry out a systematic examination of metatarsal tumours with regard to methods of diagnosis (location) and morphology.
  • MATERIAL AND METHODS: Fifteen patients with metatarsal tumours were diagnosed in the Department of Orthopaedics in Warsaw.
  • RESULTS: Most of the metatarsal tumours were benign.
  • Bone tumours are rarely located in the metatarsus.
  • 2. The presenting clinical and radiological signs of metatarsal tumours are usually not characteristic and may be difficult to detect.
  • 4. The frequently unequivocal presentation of metatarsal tumours requires a multidisciplinary diagnosis involving a clinician, a radiologist and a histopathologist.
  • [MeSH-major] Bone Neoplasms / diagnosis. Metatarsal Bones / radiography
  • [MeSH-minor] Adult. Bone Cysts, Aneurysmal / diagnosis. Diagnosis, Differential. Female. Giant Cell Tumor of Bone / diagnosis. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Osteochondroma / diagnosis. Osteoma / diagnosis. Sarcoma, Synovial / diagnosis. Soft Tissue Neoplasms / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721430.001).
  • [ISSN] 1509-3492
  • [Journal-full-title] Ortopedia, traumatologia, rehabilitacja
  • [ISO-abbreviation] Ortop Traumatol Rehabil
  • [Language] eng; pol
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


45. Eyesan SU, Ugwoegbulem OA, Obalum DC: Bone cement in the management of cystic tumour defects of bone at National Orthopaedic Hospital, Igbobi, Lagos. Niger J Clin Pract; 2009 Dec;12(4):367-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone cement in the management of cystic tumour defects of bone at National Orthopaedic Hospital, Igbobi, Lagos.
  • BACKGROUND: Cystic bony defects are characteristics of bone tumours especially benign ones e.g.
  • Giant cell tumours of bone [GCT] and some metastatic tumours to bone.
  • The objective of this study is to evaluate the outcome of filling these defects with bone cement augmented with plate and screw for stability.
  • METHOD: A seven year prospective study was carried out in patients presenting with large cystic bony defects secondary to bone tumours at the oncology unit of the National Orthopaedic Hospital, Igbobi, Lagos.
  • Data such as age, sex, anatomic location of lesions, histological type of tumours, x-ray findings, operation performed with the number of packets of bone cement used to fill the resultant bony defects were retrieved from prepared proforma.
  • Giant cell tumour was the most common histological diagnosis 78.6%.
  • Bone cement was effective in meeting the local requirements of limb salvage, early functional recovery and as a temporising measure until the patients can avail themselves of better options.
  • CONCLUSION: Bone cement augmented with appropriate implants has proven valuable as a stop gap in filling large cystic bony defects resulting from tumours.
  • [MeSH-major] Bone Cements. Bone Cysts / surgery. Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Humerus / surgery. Leg Bones / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20329673.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Bone Cements
  •  go-up   go-down


46. Szalay K, Antal I, Kiss J, Szendroi M: Comparison of the degenerative changes in weight-bearing joints following cementing or grafting techniques in giant cell tumour patients: medium-term results. Int Orthop; 2006 Dec;30(6):505-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the degenerative changes in weight-bearing joints following cementing or grafting techniques in giant cell tumour patients: medium-term results.
  • The aim of this retrospective study was to compare and assess the effect of bone grafting and cementing techniques--two common applications used in the treatment of subchondral giant cell tumours of bone (GCTs)--on the development of degenerative changes in the weight-bearing joints of the lower extremity.
  • Eighty patients were included in this follow-up study, 44 of whom underwent curettage followed by bone grafting, and 36 who had curettage followed by cementation.
  • At the 24-month post-operative examination, significantly less degenerative change was found in patients with bone cement than in those with bone grafting.
  • [MeSH-major] Bone Cements / adverse effects. Bone Neoplasms / surgery. Bone Transplantation / adverse effects. Giant Cell Tumor of Bone / surgery. Joints / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Femur / pathology. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Middle Aged. Quality of Life. Recovery of Function. Retrospective Studies. Tibia / pathology. Weight-Bearing

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Orthop Trauma Surg. 2001;121(1-2):83-6 [11195127.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:116-22 [16131879.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] J Orthop Res. 2002 May;20(3):464-72 [12038619.001]
  • [Cites] Recent Results Cancer Res. 1976;(54):257-61 [1013500.001]
  • [Cites] J Orthop Res. 1984;2(3):221-34 [6436458.001]
  • [Cites] Clin Orthop Relat Res. 1986 Jun;(207):290-305 [3522015.001]
  • [Cites] Clin Orthop Relat Res. 1986 Dec;(213):34-40 [3780104.001]
  • [Cites] J Orthop Res. 1989;7(4):579-84 [2544712.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Clin Orthop Relat Res. 1993 Aug;(293):378-90 [8339507.001]
  • [Cites] J Bone Joint Surg Br. 1995 Mar;77(2):189-93 [7706330.001]
  • [Cites] Clin Orthop Relat Res. 1995 Dec;(321):245-50 [7497676.001]
  • [Cites] Clin Orthop Relat Res. 1997 Apr;(337):240-8 [9137195.001]
  • [Cites] Changgeng Yi Xue Za Zhi. 1998 Mar;21(1):37-43 [9607262.001]
  • [Cites] Clin Orthop Relat Res. 1999 Feb;(359):176-88 [10078141.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Int Orthop. 2005 Feb;29(1):30-4 [15647917.001]
  • [Cites] J Biomed Mater Res. 2002 Mar 5;59(3):490-8 [11774307.001]
  • (PMID = 16969579.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bone Cements
  • [Other-IDs] NLM/ PMC3172737
  •  go-up   go-down


47. Zhang Z, Zhu B, Sun T: [Case analysis on treatment and recurrence of giant cell tumor of bone]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct;20(10):1007-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case analysis on treatment and recurrence of giant cell tumor of bone].
  • OBJECTIVE: To analyze the clinical features, treatment methods, and recurrence factors of giant cell tumor of the bone and to investigate the surgical therapy choice for the tumor around the knees.
  • METHODS: Thirty-eight patients (13 males and 25 females; average age 31.1 years, range 14-59 years) with giant cell tumor of the bone were treated and followed up from January 1993 to January 2005.
  • The intralesional excision (curettage) with the bone grafting was performed on 4 patients; the curettage with some adjuvant treatments (high-speed burring, phenol, alcohol, cement, hydrogen peroxide, 50% ZnCl2, 3% iodine tincture, or bone cement) was used in 26 patients; and resection of the whole tumor was performed on 8 patients.
  • RESULTS: The follow-up of the 38 patients for 12-144 months (average, 67 months) revealed that giant cell tumor of the bone was found around the knees in 29 of the 38 patients (13 at the distal femur, 16 at the proximal tibia), at the proximal femur in 2, at the proximal ulna in 2, at the distal radius in 2, at the sacroiliac area in 2, and at lumbar spine in 1.
  • Of the 38 patients, 4 had a recurrence after simple curettage, 8 had no recurrence after resection of the whole tumor, and 8 of the remaining 26 patients had a recurrence after curettage with some adjuvant treatments.
  • Of the patients with the recurrence, 12 underwent reoperations (8 by the total resection of the recurrent tumor, 4 by the curettage with adjuvant treatments), and there was no recurrence after the reoperation.
  • CONCLUSION: Giant cell tumor of the bone usually recurs around the knee joint, especially at the proximal tibia, usually graded as Grade II or III by the Campanacci's radiological grading system.
  • Simple curettage has a higher recurrence rate; therefore, extensive curettage and resection of the lesions combined with some adjuvant treatments after the correct diagnosis can be used to reduce the high recurrence rate of giant cell tumor of the bone.
  • [MeSH-major] Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / surgery. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140075.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. Mondal SK: Cytodiagnosis of benign fibrous histiocytoma of rib and diagnostic dilemma: a case report. Diagn Cytopathol; 2010 Jun;38(6):457-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytodiagnosis of benign fibrous histiocytoma of rib and diagnostic dilemma: a case report.
  • Benign fibrous histiocytoma (BFH) of bone is rare in occurrence, and rib is an unusual site.
  • There are limited case reports of this entity in the literature, and cytodiagnosis of this tumor is not described.
  • Radiological investigations (plain radiograph and computed tomography) revealed a lytic bone lesion involving the 5th rib.
  • Radiologically, giant cell tumor (GCT), BFH, and plasmacytoma were suspected.
  • In fine-needle aspiration cytology (FNAC), admixture of benign stromal cells and scattered osteoclast type giant cells were found in the smears.
  • Differential diagnoses of BFH, GCT (non-epiphyseal type), fibrous dysplasia, and aneurysmal bone cyst were made on cytology.
  • Subsequent histologic examination confirmed the diagnosis of BFH.
  • Cytologic diagnosis of BFH of rib is difficult as this tumor may mimic other giant cell containing tumors of bone in FNAC.
  • The final diagnosis should always be made after correlation with histological, radiological, and clinical features.
  • [MeSH-major] Bone Neoplasms / pathology. Histiocytoma, Benign Fibrous / pathology. Ribs / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Bone Cysts, Aneurysmal / pathology. Cytodiagnosis. Diagnosis, Differential. Fibrous Dysplasia of Bone / pathology. Giant Cell Tumors / pathology. Humans. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 20014125.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML: Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol; 2009 Jul 01;27(19):3154-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
  • PURPOSE To evaluate the potential benefit of continuous daily dosing sunitinib in patients with advanced nongastrointestinal stromal tumor (GIST) sarcomas.
  • Secondary end points were stable disease at 16 and 24 weeks.
  • One patient (desmoplastic round cell tumor [DSRCT]) achieved a confirmed partial response (PR) and remained on study for 56 weeks.
  • Ten patients (20%) achieved stable disease for at least 16 weeks.
  • Metabolic stable disease was seen in 11 (52%) of 21.
  • The relevance of disease control observed in subtypes with an indolent natural history is unknown, however, the durable disease control observed in DSRCT, solitary fibrous tumor, and giant cell tumor of bone suggests that future evaluation of sunitinib in these subtypes may be warranted.
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome. Young Adult


50. Sakayama K, Sugawara Y, Kidani T, Miyawaki J, Fujibuchi T, Kamei S, Aizawa J, Yamamoto H: Diagnostic and therapeutic problems of giant cell tumor in the proximal femur. Arch Orthop Trauma Surg; 2007 Dec;127(10):867-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and therapeutic problems of giant cell tumor in the proximal femur.
  • Primaly giant cell tumor of bone (GCT) in the proximal femur is relatively rare, and can prove difficult to diagnose, and can require therapeutic methods.
  • The long-term follow-up reveals that one of the important problem is pre-operative diagnosis.
  • [MeSH-major] Femoral Neoplasms / diagnosis. Femoral Neoplasms / surgery. Giant Cell Tumor of Bone / diagnosis. Giant Cell Tumor of Bone / surgery
  • [MeSH-minor] Adult. Arthrodesis. Arthroplasty, Replacement, Hip / methods. Biopsy. Bone Cements / therapeutic use. Female. Femur / pathology. Femur / surgery. Hip Joint / surgery. Humans. Male. Neoplasm Recurrence, Local. Osteolysis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713773.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bone Cements
  •  go-up   go-down


56. Karpik M: Giant Cell Tumor (tumor gigantocellularis, osteoclastoma) - epidemiology, diagnosis, treatment. Ortop Traumatol Rehabil; 2010 May-Jun;12(3):207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant Cell Tumor (tumor gigantocellularis, osteoclastoma) - epidemiology, diagnosis, treatment.
  • The author presents the epidemiology, classification, clinical features and strategies of treatment of Giant Cell Tumor.
  • Giant Cell Tumor of Bone accounts for 4-8% of primary bone tumors.
  • Increasing pain at the tumor site is the most common presenting symptom.
  • The recurrence rate is high (12-50%) during the first 2-3 years after surgery, regardless of pre-operative tumor stage.
  • 5-7% cases of giant cell tumor produce malignant recurrences, usually after five to more than 10 years after surgery.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / surgery. Giant Cell Tumor of Bone / diagnosis. Giant Cell Tumor of Bone / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Risk Assessment. Risk Factors. Secondary Prevention. Sex Distribution. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20675862.001).
  • [ISSN] 1509-3492
  • [Journal-full-title] Ortopedia, traumatologia, rehabilitacja
  • [ISO-abbreviation] Ortop Traumatol Rehabil
  • [Language] eng; pol
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  •  go-up   go-down


57. Knowles HJ, Athanasou NA: Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis. J Pathol; 2009 Jun;218(2):256-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoclasts are the primary mediators of pathological bone resorption in many conditions in which micro-environmental hypoxia is associated with disease progression.
  • Mature human osteoclasts were differentiated from peripheral blood or obtained from giant cell tumour of bone.
  • Transient reoxygenation returned the percentage of trypan blue-positive cells to normoxic levels, suggesting that osteoclasts can recover from the early stages of cell death.
  • These data suggest that in diseased bone, where the pO(2) may fall to <or=2% O(2), a delicate balance between hypoxia-induced osteoclast activation and hypoxia-induced osteoclast apoptosis mediates pathological bone resorption.
  • [MeSH-major] Bone Resorption / pathology. Cell Hypoxia / physiology. Osteoclasts / pathology
  • [MeSH-minor] Apoptosis. Biomarkers / analysis. Cathepsin K. Cathepsins / analysis. Cathepsins / metabolism. Cell Differentiation. Cell Membrane / metabolism. Coloring Agents / analysis. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / analysis. Hypoxia-Inducible Factor 1, alpha Subunit / genetics. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. In Situ Nick-End Labeling. Oxygen / pharmacology. RNA Interference. RNA, Small Interfering / pharmacology. Receptors, Thrombin / analysis. Receptors, Thrombin / metabolism. Trypan Blue / analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trypan blue .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291710.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Coloring Agents; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Small Interfering; 0 / Receptors, Thrombin; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K; I2ZWO3LS3M / Trypan Blue; S88TT14065 / Oxygen
  •  go-up   go-down


58. Aggarwal AN, Jain AK, Kumar S, Dhammi IK, Prashad B: Reconstructive procedures for segmental resection of bone in giant cell tumors around the knee. Indian J Orthop; 2007 Apr;41(2):129-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstructive procedures for segmental resection of bone in giant cell tumors around the knee.
  • BACKGROUND: Segmental resection of bone in Giant Cell Tumor (GCT) around the knee, in indicated cases, leaves a gap which requires a complex reconstructive procedure.
  • After resection arthrodesis with intercalary autograft and simultaneous lengthening the resultant gap (∼15cm) was partially bridged by intercalary nonvascularized dual fibular strut graft (6-7cm) and additional corticocancellous bone graft from ipsilateral patella.
  • The stress fracture fibula required DCP fixation and bone grafting.
  • CONCLUSION: Resection arthrodesis with intercalary dual fibular autograft and cortico-cancellous bone grafting with simultaneous limb lengthening achieved limb length equalization with relatively short morbidity.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139765.001).
  • [ISSN] 0019-5413
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2989136
  • [Keywords] NOTNLM ; Enbloc resection / giant cell tumor / reconstruction of knee
  •  go-up   go-down


59. Niu XH, Hao L, Zhang Q, Ding Y: [Massive allograft replacement in management of bone tumors]. Zhonghua Wai Ke Za Zhi; 2007 May 15;45(10):677-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Massive allograft replacement in management of bone tumors].
  • OBJECTIVE: To evaluate the functional outcome and the complications of allograft replacement in management of bone tumors.
  • METHODS: Between March 1992 and September 2002 164 patients underwent bone tumor resection and massive allograft reconstruction of bone defects.
  • The resections were classified as marginal or wide resections of the tumor on the basis of the Musculoskeletal Tumor Society staging system.
  • Most of the lesions were osteosarcoma and giant cell tumor of bone and located in proximal and distal femur, proximal tibia and humerus.
  • RESULTS: At a median follow-up of 47 months (range, 12 to 168 months) after the operation, 154 of the patients in the study were free of disease and 10 died of disease.
  • CONCLUSIONS: Allografts can be used for reconstruction of bony defects after tumor resection.
  • Allograft has nearly similar shape, strength, osteo-conduction and osteo-induction with host bone.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Substitutes. Bone Transplantation / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688819.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Substitutes
  •  go-up   go-down


60. Bello Báez A, López Pino MA, Azorín Cuadrillero D, Sirvent Cerdá S: [Aneurysmatic bone cyst coexisting with osteosarcoma. Radiopathologic discussion]. Radiologia; 2010 May-Jun;52(3):247-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aneurysmatic bone cyst coexisting with osteosarcoma. Radiopathologic discussion].
  • Aneurysmatic bone cysts are benign lesions of unknown origin.
  • It has been postulated that they might occur in reaction to trauma or to a primary benign (giant cell tumor, chondroblastoma, etc.) or malignant (osteosarcoma) bone tumor that results in local hemodynamic changes.
  • We present a case of low grade osteosarcoma with a radiologic progression that was indistinguishable from that of an aneurysmatic bone cyst.
  • [MeSH-major] Bone Cysts, Aneurysmal / radiography. Humerus. Osteosarcoma / radiography

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 SERAM. Published by Elsevier Espana. All rights reserved.
  • (PMID = 20304449.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


61. Nishimura M, Yuasa K, Mori K, Miyamoto N, Ito M, Tsurudome M, Nishio M, Kawano M, Komada H, Uchida A, Ito Y: Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. J Orthop Res; 2005 Sep;23(5):979-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact.
  • When human blood monocytes were cocultured with stromal cells derived from human giant cell tumor of bone (GCTSC) and a Millipore filter (0.4 microm) was interposed between monocytes and GCTSC, multinucleated giant cell formation of monocytes was induced.
  • The multinucleated giant cells have characters as osteoclast-like cells, indicating that a soluble osteoclast-inducing factor(s) is secreted from GCTSC expressing RANK, RANKL/ODF/OPGL and TACE mRNA.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumors / pathology. Monocytes / cytology. Osteoclasts / physiology. Stromal Cells / physiology
  • [MeSH-minor] Alkaline Phosphatase / analysis. Carrier Proteins / genetics. Carrier Proteins / physiology. Cell Communication. Cell Lineage. Cytokines / biosynthesis. Cytokines / genetics. Humans. Membrane Glycoproteins / genetics. Membrane Glycoproteins / physiology. Osteocalcin / analysis. Osteogenesis. Osteopontin. RANK Ligand. RNA, Messenger / analysis. Receptor Activator of Nuclear Factor-kappa B. Receptors, Calcium-Sensing / genetics. Sialoglycoproteins / physiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024207.001).
  • [ISSN] 0736-0266
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CASR protein, human; 0 / Carrier Proteins; 0 / Cytokines; 0 / Membrane Glycoproteins; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / Receptors, Calcium-Sensing; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 0 / TNFRSF11A protein, human; 0 / TNFSF11 protein, human; 104982-03-8 / Osteocalcin; 106441-73-0 / Osteopontin; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


62. Swanger R, Maldjian C, Murali R, Tenner M: Three cases of benign giant cell tumor with unusual imaging features. Clin Imaging; 2008 Sep-Oct;32(5):407-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of benign giant cell tumor with unusual imaging features.
  • OBJECTIVE: Imaging findings for giant cell tumors (GCT) of the spine displaying aggressive characteristics have not been widely reported.
  • CONCLUSION: Acute fracture, subluxation, and extension through the disc space have not been previously described and, while atypical for benign lesions, may in fact be typical for GCT of the spine.
  • [MeSH-major] Fractures, Spontaneous / diagnosis. Giant Cell Tumor of Bone / diagnosis. Spinal Cord Compression / diagnosis. Spinal Fractures / diagnosis. Spinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Low Back Pain / diagnosis. Low Back Pain / etiology. Magnetic Resonance Imaging / methods. Retrospective Studies. Risk Assessment. Sampling Studies. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760733.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Forsyth RG, De Boeck G, Bekaert S, De Meyer T, Taminiau AH, Uyttendaele D, Roels H, Praet MM, Hogendoorn PC: Telomere biology in giant cell tumour of bone. J Pathol; 2008 Apr;214(5):555-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere biology in giant cell tumour of bone.
  • Giant cell tumour of bone (GCTB) is a benign bone tumour known for the unpredictable clinical behaviour of recurrences and, in rare instances, distant metastases.
  • It consists of uniformly distributed osteoclastic giant cells in a background of mononuclear rounded and spindle-shaped cells.
  • GCTB has often been regarded as a polyclonal tumour, but more recently a recurrent specific aberration was reported, which suggests a possible role for disturbed telomere maintenance.
  • Both osteoclastic giant cells and mononuclear cells showed positivity for hTERT and promyelocytic leukaemia body-related antigen.
  • [MeSH-major] Bone Neoplasms / genetics. Giant Cell Tumors / genetics. Telomere / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. In Situ Hybridization, Fluorescence. Male. Microscopy, Confocal. Middle Aged. Neoplasm Proteins / metabolism. Nuclear Proteins / metabolism. Osteoclasts / metabolism. Osteoclasts / pathology. Phosphoproteins / metabolism. RNA-Binding Proteins / metabolism. Telomerase / metabolism. Transcription Factors / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Pathological Society of Great Britain and Ireland
  • (PMID = 18278785.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / RNA-Binding Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / nucleolin; 143220-95-5 / PML protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


64. Tarrass F, Ayad A, Benjelloun M, Anabi A, Ramdani B, Benghanem MG, Zaid D: Cauda equina compression revealing brown tumor of the spine in a long-term hemodialysis patient. Joint Bone Spine; 2006 Dec;73(6):748-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cauda equina compression revealing brown tumor of the spine in a long-term hemodialysis patient.
  • Brown tumors, or osteoclastomas, are erosive bony lesions arising as a complication of hyperparathyroidism (HPT).
  • In patients with end-stage renal disease (ESRD), brown tumors are classic skeletal manifestations usually seen in severe forms of secondary HPT.
  • We report a long-term hemodialysis case, in which cauda equina compression developed due to a sacral brown tumor.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16650789.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


65. Guliaeva SS, Voloshchuk IN, Mokrysheva NG, Rozhinskaia LIa: [Maldiagnosis of giant-cell tumor of the bone in a patient with hyperparathyroid osteodystrophy]. Arkh Patol; 2009 Sep-Oct;71(5):53-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Maldiagnosis of giant-cell tumor of the bone in a patient with hyperparathyroid osteodystrophy].
  • The paper describes a case of maldiagnosis of giant-cell tumor in a patient with parathyroid osteodystrophy, in this connection elbow joint resection and replacement were made.
  • Progression of diseases was accompanied by severe bone changes and the development of urolithiasis complicated by chronic renal failure.
  • Thus, the interpretation of bone tissue changes without considering clinical and laboratory data led to the unwarranted surgical intervention and the late diagnosis of primary hyperparathyroidism.
  • Differential diagnosis of a giant-cell tumor should be made, by obligatorily considering clinical and laboratory data, including the parameters of calcium metabolism.
  • [MeSH-major] Bone Diseases, Metabolic / pathology. Bone Neoplasms / pathology. Carcinoma, Giant Cell / pathology. Hyperparathyroidism / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. False Positive Reactions. Humans. Male

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19938706.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


66. Cosso R, Nuzzo V, Zuccoli A, Brandi ML, Falchetti A: Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent. Clin Cases Miner Bone Metab; 2010 May;7(2):145-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent.
  • Giant cell tumor of bone, also called osteoclastoma, is a rare skeletal complication of Paget's disease of bone.
  • We will focus on either a review on this rare bone tumor, including some genetic aspects, or the current established therapies.
  • Finally, we will describe the therapeutic outcomes of this unique complication of Paget's disease of bone as a rapid response to an innovative therapeutic agent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22460021.001).
  • [ISSN] 1971-3266
  • [Journal-full-title] Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
  • [ISO-abbreviation] Clin Cases Miner Bone Metab
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3004463
  •  go-up   go-down


67. Lentini M, Zuccalà V, Fazzari C: Polypoid giant cell tumor of the skin. Am J Dermatopathol; 2010 Feb;32(1):95-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypoid giant cell tumor of the skin.
  • Giant cell tumor of soft tissue is a rare neoplasm named for its resemblance to giant cell tumor of bone.
  • The histomorphological features were consistent with the diagnosis of primary giant cell tumor of the skin.
  • Clinical informations and immunohistochemistry are useful in distinguishing this neoplasm from other neoplastic and reactive lesions of the superficial soft tissues containing giant cells.
  • [MeSH-major] Giant Cell Tumors / pathology. Paranasal Sinus Neoplasms / pathology. Skin Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Female. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19915451.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


68. Liu HS, Di X: Endoscopic endonasal surgery for biopsy of cavernous sinus lesions. Minim Invasive Neurosurg; 2009 Apr;52(2):69-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The accuracy of the diagnosis with this technique was 100%.
  • The pathological diagnosis of the cavernous sinus lesions showed 3 patients with nasopharyngeal carcinoma, 2 patients with meningioma, 1 patient with esthesioneuroblastoma, 1 giant cell tumor of bone, 1 small cell carcinoma from the lungs, 1 fungal granuloma, and 1 schwannoma.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452412.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


69. Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine TA, Parisien MV, Kim W, Winchester RJ, Lee FY: Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res; 2005 Jan;23(1):203-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone.
  • Giant cell tumor (GCT) of bone is a unique bone lesion that is characterized by an excessive number of multinucleated osteoclasts.
  • GCT consists of neoplastic stromal cells, multinucleated osteoclasts and their precursors, thus serving as a naturally occurring human disease model for the study of osteoclastogenesis.
  • These results suggest that SDF-1 is one of the significant chemoattractant factors involved in the recruitment of hematopoietic osteoclast precursor cells during tumor-induced osteoclastogenesis.
  • [MeSH-major] Bone Neoplasms / pathology. Chemokines, CXC / physiology. Giant Cell Tumor of Bone / pathology. Osteoclasts / physiology. Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607894.001).
  • [ISSN] 0736-0266
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC
  •  go-up   go-down


70. James SL, Davies AM: Giant-cell tumours of bone of the hand and wrist: a review of imaging findings and differential diagnoses. Eur Radiol; 2005 Sep;15(9):1855-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell tumours of bone of the hand and wrist: a review of imaging findings and differential diagnoses.
  • Giant-cell tumour of bone (GCTOB) is a benign, locally aggressive, primary bone tumour.
  • The role of bone scintigraphy, computed tomography and magnetic resonance imaging is discussed.
  • [MeSH-major] Bone Neoplasms / diagnosis. Carpal Bones / pathology. Diagnostic Imaging. Giant Cell Tumor of Bone / diagnosis. Hand Bones / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Radiopharmaceuticals. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1985 Jul;67(6):890-900 [4019539.001]
  • [Cites] J Bone Joint Surg Am. 1983 Oct;65(8):1179-80 [6355113.001]
  • [Cites] Orthopedics. 1995 May;18(5):482-4 [7610097.001]
  • [Cites] Clin Radiol. 1998 Jul;53(7):481-9 [9714386.001]
  • [Cites] Skeletal Radiol. 1987;16(8):635-43 [3423832.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • [Cites] AJR Am J Roentgenol. 2004 Nov;183(5):1453-63 [15505320.001]
  • [Cites] Orthopedics. 2001 Nov;24(11):1085-6 [11727811.001]
  • [Cites] J Hand Surg Am. 1977 Jul;2(4):269-70 [893983.001]
  • [Cites] AJR Am J Roentgenol. 2003 Dec;181(6):1583-9 [14627578.001]
  • [Cites] Radiology. 1992 Jul;184(1):233-7 [1609086.001]
  • [Cites] Hand. 1982 Feb;14 (1):93-6 [6277748.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Clin Orthop Relat Res. 1996 Feb;(323):60-4 [8625607.001]
  • [Cites] Clin Orthop Relat Res. 1989 Jun;(243):208-15 [2656024.001]
  • [Cites] Eur Radiol. 2003 Aug;13(8):1820-35 [12700923.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Hand Surg Am. 1994 Nov;19(6):1003-5 [7876470.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] J Hand Surg Am. 1980 Jan;5(1):39-50 [7365216.001]
  • [Cites] J Hand Surg Am. 2004 Mar;29(2):188-93 [15043887.001]
  • [Cites] Clin Radiol. 2000 Sep;55(9):717-8 [10988053.001]
  • [Cites] J Hand Surg Am. 1995 May;20(3):432-40 [7642922.001]
  • [Cites] Clin Orthop Relat Res. 2001 Feb;(383):221-8 [11210959.001]
  • [Cites] Radiologe. 2001 Jul;41(7):577-82 [11490778.001]
  • [Cites] Ann R Coll Surg Engl. 2004 Jan;86(1):18-24 [15005940.001]
  • [Cites] J Bone Joint Surg Am. 1977 Dec;59(8):1052-60 [591535.001]
  • [Cites] J Bone Joint Surg Br. 1995 Mar;77(2):189-93 [7706330.001]
  • [Cites] Clin Orthop Relat Res. 1996 Jan;(322):245-52 [8542701.001]
  • [Cites] Orthopedics. 1997 Jan;20(1):67-9 [9122055.001]
  • [Cites] J Bone Joint Surg Am. 1980;62(4):652-6 [7380862.001]
  • [Cites] J Hand Surg Am. 1977 Jul;2(4):299-308 [330615.001]
  • [Cites] Radiology. 1998 Sep;208(3):821-8 [9722866.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 1981 Aug;119(4):427-9 [7293356.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):204-5 [2249533.001]
  • [Cites] Clin Orthop Relat Res. 1992 Jan;(274):270-4 [1729012.001]
  • [Cites] Cancer. 1979 Oct;44(4):1393-402 [227563.001]
  • [Cites] Ann Plast Surg. 1996 Jul;37(1):55-9 [8826593.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] Orthopade. 2000 Jul;29(7):677-83 [10986714.001]
  • [Cites] J Bone Joint Surg Am. 1983 Apr;65(4):486-90 [6833323.001]
  • [Cites] Cancer. 1970 May;25(5):1061-70 [4910256.001]
  • [Cites] Cancer. 2000 May 1;88(9):2022-32 [10813712.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] J Hand Surg Am. 1987 Jan;12 (1):70-7 [3805646.001]
  • [Cites] J Hand Surg Am. 1984 May;9(3):391-8 [6725899.001]
  • [Cites] J Hand Surg Am. 1997 Jan;22(1):91-8 [9018620.001]
  • [Cites] Skeletal Radiol. 1990;19(2):85-90 [2321049.001]
  • [Cites] Clin Orthop Relat Res. 1998 Jul;(352):187-93 [9678047.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):269-74 [6693454.001]
  • [Cites] Eur Radiol. 2004 Oct;14 (10 ):1761-9 [15221263.001]
  • [Cites] Radiology. 1983 Oct;149(1):65-8 [6611953.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jan;166(1):145-8 [8571864.001]
  • [Cites] J Bone Joint Surg Am. 1986 Jun;68(5):687-94 [3722225.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 2000 Dec;34(4):397-9 [11195881.001]
  • [Cites] J Surg Oncol. 1983 Oct;24(2):99-102 [6632902.001]
  • [Cites] J Hand Surg Am. 1984 Mar;9(2):272-4 [6715840.001]
  • [Cites] Skeletal Radiol. 1984;12 (2):79-89 [6484605.001]
  • [Cites] Semin Diagn Pathol. 1984 Aug;1(3):173-84 [6599927.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):45-58 [3514036.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jan;79(1):26-30 [9020440.001]
  • [Cites] J Hand Surg Am. 1982 Nov;7(6):593-600 [7175130.001]
  • [Cites] Med J Malaysia. 2000 Sep;55 Suppl C:105-6 [11200036.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):755-61 [7045129.001]
  • [Cites] J Hand Surg Br. 1996 Oct;21(5):683-7 [9230964.001]
  • [Cites] Clin Orthop Relat Res. 2003 Nov;(416):278-84 [14646771.001]
  • [Cites] Clin Orthop Relat Res. 1999 Feb;(359):176-88 [10078141.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] Skeletal Radiol. 1994 Apr;23(3):187-90 [8016669.001]
  • [Cites] Radiographics. 2001 Sep-Oct;21(5):1283-309 [11553835.001]
  • [Cites] Hand Clin. 2004 Aug;20(3):269-81, vi [15275686.001]
  • [Cites] J Bone Joint Surg Am. 1981 Jul;63(6):877-84 [7240328.001]
  • [Cites] Radiographics. 1990 Jan;10 (1):83-102 [2296699.001]
  • [Cites] Eur Radiol. 1998;8(5):791-9 [9601967.001]
  • [Cites] Skeletal Radiol. 1984;11(2):85-95 [6322349.001]
  • [Cites] Chir Organi Mov. 1990 Jan-Mar;75(1):77-80 [2369858.001]
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):331-4 [1729794.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jan;86(1):5-12 [14765857.001]
  • [Cites] J Bone Joint Surg Am. 1986 Feb;68(2):235-42 [3511063.001]
  • [Cites] J Bone Joint Surg Am. 1996 Jan;78(1):106-10 [8550667.001]
  • [Cites] J Hand Surg Br. 1998 Apr;23(2):279-80 [9607683.001]
  • [Cites] Skeletal Radiol. 1992;21(5):335-8 [1502590.001]
  • (PMID = 15868123.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals
  • [Number-of-references] 89
  •  go-up   go-down


71. Qin H, Cai J, Fang J, Xu H, Gong Y: Could MTA be a novel medicine on the recurrence therapy for GCTB? Med Hypotheses; 2010 Feb;74(2):368-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Giant cell tumor of bone (GCTB) is a benign locally aggressive bone tumor with a shown clinical behavior of local recurrences and rare distant metastases.
  • Due to the high rate of pulmonary metastases recurrent GCTB may be considered as a severe disease.
  • If the tumor reaches close to the articulating surface a subchondral bone graft can be performed without risking a higher recurrence rate.
  • MTA is a powder aggregate containing mineral oxides with a good biological action and may facilitate the regeneration of the periodontal ligament and formation of bone.
  • MTA used was able to induce bone regeneration and had its action optimized.
  • For the clinical point of view, we can apply MTA in the GCTB to induce bone production, then to inhibit the recurrent of the cases.
  • MTA may be the therapy of choice for primary as well as recurrent giant cell tumors of bone.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / physiopathology. Giant Cell Tumor of Bone / drug therapy. Giant Cell Tumor of Bone / physiopathology. Glutamates / administration & dosage. Guanine / analogs & derivatives. Neoplasm Recurrence, Local / physiopathology. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656634.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


72. Dominkus M, Ruggieri P, Bertoni F, Briccoli A, Picci P, Rocca M, Mercuri M: Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution. Int Orthop; 2006 Dec;30(6):499-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution.
  • From 1975 to 1997, 649 cases of benign giant cell tumours of the bone were treated at the Istituto Rizzoli.
  • The time interval between the diagnosis and the appearance of the lung metastases ranged from 3 months to 11.9 years.
  • Histologically, the metastases were identical to the primary bone lesions.
  • Ten patients showed no evidence of disease, one of these after a second resection of metastases, and four patients presented stable disease with multiple lung metastases.
  • Local recurrence of the bone lesion occurred in seven patients before or simultaneously to the metastases.
  • In contrast to previous reports, we could not detect a predominance of the distal radius, but all of the patients had a stage III tumour according to the Enneking criteria of benign lesions.
  • We conclude that even metastatic benign giant cell tumours have an excellent prognosis after adequate resection.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Orthop Surg (Hong Kong). 2004 Jun;12(1):55-62 [15237123.001]
  • [Cites] J Bone Joint Surg Am. 1959 Jul;41-A(5):895-904 [13664723.001]
  • [Cites] Ann Thorac Surg. 1973 Nov;16(5):531-5 [4746080.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):269-74 [6693454.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2564-7 [6498747.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] N Engl J Med. 1988 Feb 25;318(8):517 [3340133.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] J Bone Joint Surg Br. 1989 May;71(3):432-3 [2722935.001]
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):331-4 [1729794.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] J Bone Joint Surg Am. 1996 Jan;78(1):106-10 [8550667.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Bone Joint Surg Br. 1957 May;39-B(2):346-57 [13438979.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • (PMID = 16909252.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3172731
  •  go-up   go-down


73. Kafchitsas K, Habermann B, Proschek D, Kurth A, Eberhardt C: Functional results after giant cell tumor operation near knee joint and the cement radiolucent zone as indicator of recurrence. Anticancer Res; 2010 Sep;30(9):3795-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional results after giant cell tumor operation near knee joint and the cement radiolucent zone as indicator of recurrence.
  • BACKGROUND: Giant cell tumor of bone near the knee joints is a dilemma for the operating surgeon.
  • Curettage and bone grafting have a high recurrence, whereas wide resection has a reduced recurrence rate with the compromise of limb function.
  • MATERIALS AND METHODS: Thirty-eight patients with histologically proven giant cell tumor near the knee joint were treated.
  • All patients underwent surgery, 21 patients were treated with a bone cement filling and additional osteosynthesis after curettage.
  • Seventeen patients were filled with cancellous bone or curettage alone.
  • In the group with bone cement filling after curettage, the recurrence rate was 23.8%, whereas a recurrence rate of 52.9% was detected in the group with cancellous bone filling or curettage alone.
  • Patients with giant cell tumor of bone near the knee joint can be treated satisfactorily with intralesional resection and bone cement packing.
  • The extension of the radiolucent zone after bone cement filling is a reliable indicator for a possible local recurrence.
  • [MeSH-major] Bone Cements / therapeutic use. Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Knee Joint / surgery. Recovery of Function
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Orthopedic Procedures / adverse effects. Orthopedic Procedures / methods. Osteoarthritis / epidemiology. Osteoarthritis / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944172.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Bone Cements
  •  go-up   go-down


74. Salerno M, Avnet S, Alberghini M, Giunti A, Baldini N: Histogenetic characterization of giant cell tumor of bone. Clin Orthop Relat Res; 2008 Sep;466(9):2081-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histogenetic characterization of giant cell tumor of bone.
  • The unpredictable behavior of giant cell tumor (GCT) parallels its controversial histogenesis.
  • Multinucleated giant cells, stromal cells, and CD68(+) monocytes/macrophages are the three elements that interact in GCT.
  • Although stromal cells expressed early osteogenic markers, they were unable to differentiate into osteoblasts but they did express intracellular adhesion molecule-1, a marker of bone-lining cells.
  • They might be secondarily induced to proliferate by a paracrine effect induced by monocyte-macrophages and/or giant cells.
  • The increased number of giant cells in GCT may be secondary to an autocrine circuit mediated by the receptor activator of nuclear factor kB.
  • [MeSH-major] Bone Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Giant Cell Tumor of Bone / pathology. Stromal Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Differentiation / physiology. Cell Proliferation. Coculture Techniques. Female. Humans. Hyperplasia. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 1999 Nov;31(4):373-8 [10643009.001]
  • [Cites] Skeletal Radiol. 1997 Apr;26(4):246-55 [9151375.001]
  • [Cites] Cell. 1997 May 30;89(5):747-54 [9182762.001]
  • [Cites] Cell. 1997 May 30;89(5):755-64 [9182763.001]
  • [Cites] Science. 1998 Jan 16;279(5349):349-52 [9454332.001]
  • [Cites] J Orthop Res. 1998 Jan;16(1):1-7 [9565066.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4138-45 [9751626.001]
  • [Cites] J Biol Chem. 1999 Mar 12;274(11):6972-8 [10066751.001]
  • [Cites] J Bone Joint Surg Br. 1952 Feb;34-B(1):93-6 [12999882.001]
  • [Cites] Am J Pathol. 1953 Nov-Dec;29(6):1123-31 [13104637.001]
  • [Cites] J Orthop Res. 2005 Jan;23(1):203-9 [15607894.001]
  • [Cites] FASEB J. 2005 Mar;19(3):410-2 [15611151.001]
  • [Cites] Calcif Tissue Int. 2005 Mar;76(3):222-30 [15692727.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):117-28 [15972958.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):945-54 [16153456.001]
  • [Cites] J Orthop Sci. 2005 Nov;10(6):581-8 [16307183.001]
  • [Cites] Clin Lab. 2006;52(9-10):499-509 [17078477.001]
  • [Cites] Biomaterials. 2007 Feb;28(6):1132-40 [17118444.001]
  • [Cites] BMC Genomics. 2007;8:70 [17352823.001]
  • [Cites] J Orthop Res. 2005 Sep;23(5):979-87 [16024207.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):761-7 [10702390.001]
  • [Cites] Anticancer Res. 2000 Jul-Aug;20(4):2463-7 [10953311.001]
  • [Cites] J Bone Miner Res. 2000 Oct;15(10):1912-23 [11028443.001]
  • [Cites] J Orthop Res. 2000 Jul;18(4):647-54 [11052502.001]
  • [Cites] Histol Histopathol. 2001 Jan;16(1):297-307 [11193206.001]
  • [Cites] Clin Sci (Lond). 2000 Aug;99(2):133-40 [10918046.001]
  • [Cites] J Bone Miner Res. 2002 Jan;17(1):77-90 [11771672.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):203-13 [11902575.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):983-93 [14608531.001]
  • [Cites] Bone. 2004 Mar;34(3):393-401 [15003787.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):593-600 [15277232.001]
  • [Cites] Int J Cancer. 2004 Oct 10;111(6):829-38 [15300794.001]
  • [Cites] Clin Orthop Relat Res. 1981 Sep;(159):257-64 [7285463.001]
  • [Cites] J Bone Joint Surg Am. 1985 Mar;67(3):404-13 [2579083.001]
  • [Cites] J Pathol. 1985 Nov;147(3):153-8 [4067733.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] J Clin Invest. 1987 Feb;79(2):483-91 [3027126.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Bone Miner. 1992 Jan;16(1):37-48 [1531620.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1751-60 [8095436.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):806-14 [7828130.001]
  • [Cites] J Bone Miner Res. 1995 Oct;10(10):1462-9 [8686501.001]
  • [Cites] J Bone Miner Res. 2000 Jan;15(1):2-12 [10646108.001]
  • (PMID = 18543051.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2492994
  •  go-up   go-down


75. Balke M, Campanacci L, Gebert C, Picci P, Gibbons M, Taylor R, Hogendoorn P, Kroep J, Wass J, Athanasou N: Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer; 2010;10:462
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
  • BACKGROUND: Giant cell tumour of bone (GCTB) is an expansile osteolytic tumour which contains numerous osteoclast-like giant cells.
  • RESULTS: Treatment protocols differed with several different aminobisphosphonates being employed, but stabilisation of disease was achieved in most of these cases which were refractory to conventional treatment.
  • Most inoperable sacral/pelvic tumours did not increase in size and no further recurrence was seen in GCTBs that had repeatedly recurred in bone and soft tissues.
  • CONCLUSION: Our findings suggest that bisphosphonates may be useful in controlling disease progression in GCTB and that these agents directly inhibit GCTB - derived osteoclast resorption.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Diphosphonates / therapeutic use. Giant Cell Tumor of Bone / drug therapy. Imidazoles / therapeutic use. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Resorption. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Osteoclasts / drug effects. Osteoclasts / pathology. Treatment Outcome. Tumor Cells, Cultured. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):35-51 [16311110.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):96-9 [16462511.001]
  • [Cites] J Dent Res. 2007 Nov;86(11):1022-33 [17959891.001]
  • [Cites] Bone. 2008 Jan;42(1):68-73 [17962092.001]
  • [Cites] J Med Assoc Thai. 2008 Oct;91(10):1609-12 [18972907.001]
  • [Cites] Skeletal Radiol. 2009 Jan;38(1):5-9 [18649076.001]
  • [Cites] J Pain Symptom Manage. 2009 Aug;38(2):244-57 [19364633.001]
  • [Cites] Lancet Oncol. 2010 Mar;11(3):275-80 [20149736.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):945-54 [16153456.001]
  • [Cites] Clin Orthop Relat Res. 2000 Apr;(373):104-14 [10810467.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2961-78 [10898340.001]
  • [Cites] Clin Orthop Relat Res. 2001 Jan;(382):6-12 [11154006.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jan;23(1):54-6 [11196272.001]
  • [Cites] Ultrastruct Pathol. 2003 Nov-Dec;27(6):385-91 [14660277.001]
  • [Cites] Postgrad Med J. 2004 Apr;80(942):190-5 [15082837.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):103-9 [15346059.001]
  • [Cites] Calcif Tissue Int. 2004 Jul;75(1):71-7 [15037971.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] J Clin Pathol. 1990 Dec;43(12):997-1003 [2266187.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):465-71 [7526033.001]
  • [Cites] J Bone Miner Res. 1995 Oct;10(10):1478-87 [8686503.001]
  • [Cites] Acta Orthop Scand. 1996 Jun;67(3):221-8 [8686457.001]
  • [Cites] Bone. 1996 Jan;18(1):9-14 [8717530.001]
  • [Cites] J Bone Miner Res. 1997 Oct;12(10):1746-52 [9333137.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:375-88 [9597160.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • (PMID = 20799989.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  • [Other-IDs] NLM/ PMC2940802
  •  go-up   go-down


76. Cozzolino A, Balleri P, Ruggiero G, Veltri M: Use of short implants for functional restoration of the mandible after giant cell tumor removal. Case report. Minerva Stomatol; 2006 May;55(5):307-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of short implants for functional restoration of the mandible after giant cell tumor removal. Case report.
  • The giant cell tumor of the jaws is a rare benign lesion, it has a slow and progressive evolution and it is locally aggressive.
  • Diagnosis is made by radiological and histological examination and surgical treatment is necessary.
  • The clinical case of a 28-year-old man affected by a giant cell tumor of the mandible with an aggressive clinical and radiographical behaviour is reported.
  • The patient showed a jaw swelling covered by hyperemic fibro-mucous tissue from tooth 4.6 to 3.4, absence of cortical bone and mobility of teeth.
  • The giant cell tumor diagnosis was made with orthopantomography (OPT), computed tomography (CT) and needle biopsy.
  • The lesion was surgically removed and histological examination confirmed the diagnosis.
  • In spite of the wide loss of bony substance after surgery, the patient was provided with an implant supported fixed prosthesis without previous bone graft.
  • In this case short implants allowed the prosthetic rehabilitation of a mandible with severe ''resorption'' due to surgical removal of a tumor.
  • Implants were placed in the residual bone volume and successfully used to support a fixed prosthesis.
  • [MeSH-major] Dental Implantation, Endosseous. Dental Implants. Giant Cell Tumor of Bone / surgery. Mandibular Neoplasms / surgery
  • [MeSH-minor] Adult. Bone Resorption. Equipment Design. Humans. Male. Time Factors. Tooth Extraction. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16688107.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Dental Implants
  •  go-up   go-down


77. Sehli H, Daoud L, Ben Mbarek R, Ghorbel R, Ben Abdelghani K, Charfi H, Cheour I, Tarhouni L, Sellami S: [Osteomalacia and giant cell tumor: a rare case]. Tunis Med; 2008 Sep;86(9):836-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Osteomalacia and giant cell tumor: a rare case].
  • [Transliterated title] Ostéomalacie et tumeur a cellule géante: une entité rare.
  • AIM: We have investigated the mechanism by which a giant cell tumor of bone caused biopsy-proved osteomalacia in a 50-year-old woman.
  • CASE REPORT: A 50-year-old woman presented with generalized bone and pelvicrural pain, associated with fatiguability and muscle weakness.
  • The diagnosis of osteomalacia was retained, associated with a giant cell tumor.
  • The coexistence of giant cell tumor of bone and osteomalacia suggested the diagnosis of oncogenic osteomalacia.
  • Resolution of the biochemical abnormalities of the syndrome after tumor resection, established this diagnosis.
  • [MeSH-major] Bone Neoplasms / complications. Giant Cell Tumor of Bone / complications. Osteomalacia / etiology

  • Genetic Alliance. consumer health - Osteomalacia.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472787.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


78. Cağlar K, Büyük S, Caygür A, Tuğcu S, Ulutekin E: Synchronous multicentric giant cell tumor in a 16-year-old boy. Pediatr Hematol Oncol; 2005 Mar;22(2):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous multicentric giant cell tumor in a 16-year-old boy.
  • Synchronous multicentric giant cell tumor of the bone is a rare variant of a lesion appearing during childhood.
  • The authors report clinical, radiological, and pathological features of a 16-year-old boy who was diagnosed with synchronous multicentric giant cell tumor, which originated in the right distal femur and the left fibula.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805004.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Chekrine T, Tawfiq N, Bourhaleb Z, Benchakroun N, Jouhadi H, Sahraoui S, Benider A: [Giant-cell bone tumors of the spine: report of two cases and literature review]. Cancer Radiother; 2009 Sep;13(5):451-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant-cell bone tumors of the spine: report of two cases and literature review].
  • [Transliterated title] Deux cas de tumeurs osseuses à cellules géantes du rachis et revue de la littérature.
  • Giant cell tumours (GCT) are relatively rare neoplasms, most often benign.
  • The diagnosis was confirmed by histological examination in two cases.
  • [MeSH-major] Giant Cell Tumor of Bone / radiotherapy. Spinal Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615930.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


80. Eralp L, Toker B, Akgül T, Ozger H, Kocaoğlu M, Hayat S: [Applications of external fixation for management of complications associated with musculoskeletal tumors and related surgery]. Acta Orthop Traumatol Turc; 2009 May-Jul;43(3):219-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We evaluated the results of, and the course of treatment with, external fixation (EF) in treating complications associated with bone tumors and related surgery.
  • Histologic diagnoses were osteosarcoma (n=3), Ewing's sarcoma (n=3), hereditary multiple exostosis (n=3), chondrosarcoma (n=2), synovial sarcoma (n=2), Ollier's disease, giant cell tumor of bone, desmoid fibroma, chondromyxoid fibroma, and enchondroma.
  • Complications secondary to bone tumors (n=4) and occurring following limb salvage surgery (n=14) were treated with Ilizarov circular EF in nine patients, unilateral EF in six patients, and both in three patients.
  • The second group consisted of six patients who had shortening secondary to tumor surgery.
  • The third group included four patients with deformity and shortening secondary to multiple exostosis (n=3) and Ollier's disease.
  • CONCLUSION: The use of EF in the management of complications associated with bone tumors and related surgery yields successful results especially in young patients.
  • [MeSH-major] Bone Neoplasms / surgery. External Fixators / adverse effects. Fracture Fixation / methods. Muscle Neoplasms / surgery. Osteosarcoma / surgery. Postoperative Complications / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717939.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


81. Clements SE, Mellerio JE, Holden ST, McCauley J, McGrath JA: PORCN gene mutations and the protean nature of focal dermal hypoplasia. Br J Dermatol; 2009 May;160(5):1103-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Focal dermal hypoplasia (FDH) is an X-linked dominant disorder featuring developmental abnormalities of ectodermal and mesodermal tissues.
  • Both new cases showed Blaschko-linear dermal hypoplasia and extensive ectomesodermal abnormalities, including severe limb developmental anomalies and a giant cell tumour of bone in one patient.

  • Genetic Alliance. consumer health - Focal Dermal Hypoplasia.
  • Genetics Home Reference. consumer health - focal dermal hypoplasia.
  • Genetics Home Reference. consumer health - PORCN gene.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292719.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 2.3.1.- / PORCN protein, human
  •  go-up   go-down


82. Pazzaglia L, Conti A, Chiechi A, Novello C, Magagnoli G, Astolfi A, Pession A, Krenacs T, Alberghini M, Picci P, Benassi MS: Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases. Histopathology; 2010 Jul;57(1):59-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases.
  • AIMS: To identify candidate prognostic biological markers useful in selecting high-risk patients with classic primary giant cell tumours (GCT).
  • At the protein level, TNC immunoreactivity resulted in a significant difference in the disease-free survival probability curves, providing a stratification for GCT patients, useful for predicting relapse.
  • [MeSH-major] Bone Neoplasms / genetics. Giant Cell Tumor of Bone / genetics. Tenascin / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Child, Preschool. Disease-Free Survival. Female. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20653781.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Tenascin
  •  go-up   go-down


83. Ulu MO, Biceroglu H, Ozlen F, Oz B, Gazioglu N: Giant cell tumor of the frontal bone in an 18-month-old girl: a case report. Cent Eur Neurosurg; 2010 May;71(2):104-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the frontal bone in an 18-month-old girl: a case report.
  • INTRODUCTION: Giant cell tumors (GCT) are benign, but locally aggressive primary bone neoplasms, that frequently occur in the epiphyses of the long bones.
  • CASE REPORT: The authors report the management of a GCT involving the frontal bone in an 18-month-old girl.
  • CONCLUSION: Although rare, GCTs should be taken into consideration as a differential diagnosis of rapidly enlarging cranial mass lesions in pediatric patients.
  • [MeSH-major] Frontal Bone / pathology. Frontal Bone / surgery. Giant Cell Tumors / pathology. Giant Cell Tumors / surgery
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Infant. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20072990.001).
  • [ISSN] 1868-4912
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Grabellus F, Sheu SY, Schmidt B, von Winterfeld F, Schoenfeld B, Taeger G, Hillen U, Schmid KW: [Giant cell tumors of soft tissue arising in surgical scars]. Pathologe; 2009 Sep;30(5):401-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumors of soft tissue arising in surgical scars].
  • [Transliterated title] Riesenzelltumoren des Weichgewebes (mit niedrig-malignem Potenzial) in Operationsnarben.
  • Giant cell tumor of soft tissue (GCT-ST) is a rare primary soft tissue tumor with low malignant potential.
  • It is clinically and pathologically similar to the giant cell tumor of the bone.
  • Both tumors were initially regarded as tumor relapses of a leiomyosarcoma of deep soft tissue and a dermal in situ squamous cell carcinoma, respectively.
  • The period of time between initial surgical intervention and the development of the GCT-ST seems to be unusually short for the development of a "true" second neoplasm, which may underline the sometimes diffuse border between reactive "pseudosarcomatous" and neoplastic fibro-histiocytic lesions.
  • [MeSH-major] Cicatrix / pathology. Giant Cell Tumors / pathology. Neoplasms, Second Primary / pathology. Postoperative Complications / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Diagnosis, Differential. Facial Neoplasms / pathology. Facial Neoplasms / surgery. Groin / pathology. Groin / surgery. Humans. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Parotid Neoplasms / pathology. Parotid Neoplasms / secondary. Reoperation. Saphenous Vein / pathology. Saphenous Vein / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Vascular Neoplasms / pathology. Vascular Neoplasms / surgery. Venous Thrombosis / pathology. Venous Thrombosis / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Scars.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):278-80 [10971705.001]
  • [Cites] Arch Pathol. 1960 Feb;69:209-16 [14408614.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):248-56 [10680893.001]
  • [Cites] J Pathol. 1972 May;107(1):27-39 [4262633.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S54-5 [12734474.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):815-9 [9224750.001]
  • [Cites] Cancer. 1972 Jun;29(6):1518-29 [5031245.001]
  • [Cites] Burns. 2005 Jun;31(4):403-13 [15896501.001]
  • [Cites] Arch Dermatol. 1988 Apr;124(4):496-7 [3355195.001]
  • [Cites] Virchows Arch. 2006 Jun;448(6):847-51 [16596381.001]
  • [Cites] South Med J. 1994 Aug;87(8):842-4 [8052900.001]
  • [Cites] Histopathology. 2000 Sep;37(3):212-7 [10971696.001]
  • [Cites] Mod Pathol. 1999 Sep;12 (9):894-902 [10496598.001]
  • [Cites] Histopathology. 2001 Apr;38(4):379-81 [11318905.001]
  • [Cites] Diagn Cytopathol. 1998 Nov;19(5):352-4 [9812229.001]
  • [Cites] Pathologe. 1998 Jul;19(4):308-12 [9746917.001]
  • [Cites] Hum Pathol. 1996 Sep;27(9):939-43 [8816889.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1080-5 [11048801.001]
  • [Cites] Virchows Arch. 2005 Apr;446(4):438-41 [15761759.001]
  • [Cites] Am J Surg Pathol. 1994 Mar;18(3):258-65 [8116793.001]
  • [Cites] Onkologie. 2001 Apr;24(2):139-42 [11441293.001]
  • [Cites] J Orthop Res. 2002 Mar;20(2):387-90 [11918322.001]
  • [Cites] Am J Forensic Med Pathol. 1998 Jun;19(2):152-6 [9662111.001]
  • [Cites] Am J Dermatopathol. 1999 Jun;21(3):220-4 [10380041.001]
  • [Cites] Histopathology. 2005 Sep;47(3):320-1 [16115235.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):386-95 [10716152.001]
  • [Cites] Ann Plast Surg. 2000 Jul;45(1):74-7 [10917104.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403 Suppl):S110-9 [12394459.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):600-6 [9778630.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):306-11 [9060600.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jan;86(1):5-12 [14765857.001]
  • (PMID = 19367406.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Tejera-Vaquerizo A, Ruiz-Molina I, González-Serrano T, Solís-García E: Primary giant cell tumor of soft tissue in the finger. Dermatol Online J; 2008;14(6):7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary giant cell tumor of soft tissue in the finger.
  • Primary giant cell tumor of soft tissue (GCTST) arising in a finger is a rare event.
  • We report a case of a 54-year-old man with a primary finger giant cell tumor that appeared histologically identical to giant cell tumor of bone.
  • The magnetic resonance imaging showed no relation between the nodule and bone, tendons or synovial tissues.
  • The distinction of this entity from other more common primary finger tumors with giant cell morphology is emphasized.
  • [MeSH-major] Fingers / pathology. Giant Cell Tumors / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18713588.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Hoch B, Inwards C, Sundaram M, Rosenberg AE: Multicentric giant cell tumor of bone. Clinicopathologic analysis of thirty cases. J Bone Joint Surg Am; 2006 Sep;88(9):1998-2008
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric giant cell tumor of bone. Clinicopathologic analysis of thirty cases.
  • BACKGROUND: Giant cell tumor of bone accounts for 4% to 5% of primary bone tumors.
  • In this study, we describe the clinicopathologic features of thirty cases of multicentric giant cell tumor.
  • METHODS: Thirty patients who had two or more separate lesions that had been pathologically confirmed to be giant cell tumors were identified.
  • Histologic reexamination was performed to document morphologic features.
  • A minority of the tumors were confined to the metaphysis, had features of a fibro-osseous or bone-forming lesion, or arose in skeletally immature patients.
  • Secondary histopathologic changes including fibrohistiocytic regions, reactive bone formation, or aneurysmal bone cyst-like changes were not uncommon.
  • The recurrence rate was similar to that of solitary giant cell tumors.
  • Metastatic disease developed in three patients, and two patients had malignant transformation.
  • CONCLUSIONS: Multicentric giant cell tumors occur more often in younger patients than do solitary giant cell tumors, and they frequently present as synchronous lesions around the knee.
  • Some tumors appear as bone-forming or fibro-osseous tumors on imaging studies as a result of fibrohistiocytic regions and reactive bone formation.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / radiography. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / radiography. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / radiography
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Curettage. Cytoplasm / pathology. Female. Femoral Neoplasms / pathology. Femoral Neoplasms / radiography. Femoral Neoplasms / therapy. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Tibia

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951117.001).
  • [ISSN] 0021-9355
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Kiralj A, Ilić M, Markov B, Dedić S, Pejaković B, Nalić B: [Chondroma of the skull base and maxilla]. Med Pregl; 2007 Nov-Dec;60(11-12):649-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Chondromas are uncommon benign tumors of cartilaginous origin.
  • A chondroma is a painless, slow growing tumor causing destruction and exfoliation of teeth.
  • On a radiograph, the tumor appears as a cyst-like radiolucent lesion, while some are sclerotic.
  • DISCUSSION AND CONCLUSION: Chondromyxoid fibroma (CMF) is a rare, benign cartilaginous tumor that often occurs in the metaphyses of proximal tibia, proximal and distal femur and small bones of the foot.
  • The differential diagnosis is wide and includes simple or aneyrismal bone cyst, giant cell tumor, nonossifying fibroma, fibrous dysplasia, enchondroma, chondroblastoma, eosinophilic granuloma and fibrous cortical defect.
  • In the diagnosis of an intracranial chondrocytic tumor, it is important to distinguish it from enchondroma and chondrosarcoma.
  • MR provides a detailed assessment of soft tissue masses of the craniofacial region, while CT offers superior analysis of bone structure involvement.
  • The present case underlines the importance of MR examination in the diagnosis of soft tissue masses in the craniofacial region.

  • Genetic Alliance. consumer health - Chondroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666612.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


88. Lee CH, Espinosa I, Jensen KC, Subramanian S, Zhu SX, Varma S, Montgomery KD, Nielsen TO, van de Rijn M, West RB: Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod Pathol; 2008 May;21(5):531-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone.
  • Giant cell tumor of the bone (GCTOB) is a primary bone tumor that occurs mainly in young adults and is capable of locally aggressive growth.
  • Its histologic appearance can resemble a number of benign and malignant tumors but no useful diagnostic marker is known currently.
  • To identify diagnostic markers for this tumor, global gene expression profiling using cDNA microarray was performed on 6 fresh-frozen GCTOB, 3 aneurysmal bone cysts, 4 fibrous dysplasias and 12 giant cell tumors of tendon sheath/diffuse-type giant cell tumors.
  • The diagnostic utility of p63 was subsequently confirmed using anti-p63 antibody on a series of 26 GCTOB, 25 aneurysmal bone cysts, 15 chondroblastomas, 13 giant cell reparative granulomas, 13 chondromyxoid fibromas, 4 brown tumors, 4 fibrous dysplasias, 53 giant cell tumors of tendon sheath/diffuse-type giant cell tumors and 385 additional mesenchymal tumors in tissue microarrays.
  • Strong p63 nuclear staining was present in 18 of 26 (69%) GCTOB, 3 of 15 (20%) chondroblastomas and in 1 of 25 (4%) aneurysmal bone cysts while none of the other tumors commonly considered in the differential diagnosis of GCTOB showed any detectable p63 staining.
  • Strong p63 staining is rare in bone and soft-tissue tumors in general.
  • These findings altogether show that p63 can be used as a diagnostic marker to aid the clinical diagnosis of GCTOB.
  • [MeSH-major] Biomarkers, Tumor / genetics. Bone Neoplasms / genetics. Gene Expression Profiling. Giant Cell Tumor of Bone / genetics. Membrane Proteins / genetics
  • [MeSH-minor] Adult. Bone Cysts, Aneurysmal / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18192965.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


89. Abdel MP, Papagelopoulos PJ, Morrey ME, Wenger DE, Rose PS, Sim FH: Surgical management of 121 benign proximal fibula tumors. Clin Orthop Relat Res; 2010 Nov;468(11):3056-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of 121 benign proximal fibula tumors.
  • BACKGROUND: Tumors of the fibula comprise only 2.5% of primary bone lesions.
  • Patients with aggressive benign tumors in the proximal fibula may require en bloc resection.
  • QUESTIONS/PURPOSES: We therefore analyzed the incidence of peroneal nerve palsy, knee stability, and local recurrence following surgical treatment of benign proximal fibula tumors.
  • METHODS: We retrospectively reviewed the charts of 120 patients (121 tumors) with histologically confirmed aggressive benign tumors of the proximal fibula.
  • The most common diagnosis was osteochondroma (38%) followed by giant cell tumor (19%).
  • [MeSH-major] Bone Neoplasms / surgery. Fibula / surgery. Orthopedic Procedures / adverse effects
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Curettage / adverse effects. Female. Humans. Joint Instability / etiology. Joint Instability / physiopathology. Knee Joint / physiopathology. Male. Middle Aged. Neoplasm Recurrence, Local. Osteotomy / adverse effects. Peroneal Neuropathies / etiology. Range of Motion, Articular. Retrospective Studies. Surgical Wound Dehiscence / etiology. Time Factors. Treatment Outcome. Venous Thrombosis / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Sep;(402):110-21 [12218476.001]
  • [Cites] Clin Orthop Relat Res. 2007 Jan;454:198-201 [16936590.001]
  • [Cites] Surgery. 1968 Apr;63(4):588-98 [5645375.001]
  • [Cites] Surgery. 1974 Mar;75(3):377-82 [4811333.001]
  • [Cites] J Bone Joint Surg Am. 1981 Oct;63(8):1257-69 [7287796.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):755-61 [7045129.001]
  • [Cites] Am J Sports Med. 1983 Nov-Dec;11(6):404-11 [6650718.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):269-74 [6693454.001]
  • [Cites] Clin Orthop Relat Res. 1984 Jun;(186):172-81 [6723139.001]
  • [Cites] J Bone Joint Surg Am. 1986 Feb;68(2):235-42 [3511063.001]
  • [Cites] J Bone Joint Surg Am. 1986 Jun;68(5):687-94 [3722225.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1376-85 [3815310.001]
  • [Cites] J Orthop Res. 1988;6(5):621-9 [3404318.001]
  • [Cites] J Bone Joint Surg Br. 1990 Jul;72(4):723-4 [2380235.001]
  • [Cites] J Bone Joint Surg Am. 1991 Apr;73(4):575-83 [2013596.001]
  • [Cites] Clin Orthop Relat Res. 1991 Jun;(267):197-201 [2044277.001]
  • [Cites] J Bone Joint Surg Am. 1992 Sep;74(8):1180-5 [1400546.001]
  • [Cites] J Bone Joint Surg Am. 1993 Nov;75(11):1648-55 [8245057.001]
  • [Cites] J Surg Oncol. 1996 Jan;61(1):34-7 [8544457.001]
  • [Cites] J Bone Joint Surg Am. 1996 Feb;78(2):204-11 [8609110.001]
  • [Cites] Knee. 2004 Dec;11(6):489-96 [15581770.001]
  • [Cites] Arch Orthop Trauma Surg. 2005 Dec;125(10):713-20 [16267651.001]
  • [Cites] Clin Orthop Relat Res. 2003 Jan;(406):136-40 [12579012.001]
  • (PMID = 20625947.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2947668
  •  go-up   go-down


90. Grabellus F, von Winterfeld F, Sheu SY, Metz KA, Jahnke K, Schmid KW: Unusual aggressive course of a giant cell tumor of soft tissue during immunosuppressive therapy. Virchows Arch; 2006 Jun;448(6):847-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual aggressive course of a giant cell tumor of soft tissue during immunosuppressive therapy.
  • Giant cell tumor of soft tissue with low malignant potential (GCT-ST) is a low-grade, primary soft tissue sarcoma with histological and clinical features similar to giant cell tumor of the bone.
  • The main tumor localizations are the extremities, but it may also occur in the head and neck region.
  • The tumor presented with an unusual aggressive course and metastatic site: the parotid gland.
  • [MeSH-major] Giant Cell Tumors / secondary. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Parotid Neoplasms / secondary. Postoperative Complications. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aged. Heart Transplantation. Humans. Immunosuppression. Male. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):19-25 [7990861.001]
  • [Cites] Obstet Gynecol. 1998 Oct;92(4 Pt 2):667-8 [9764656.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):248-56 [10680893.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):12-8 [15842608.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1371-3 [15800234.001]
  • [Cites] Mod Pathol. 1999 Sep;12 (9):894-902 [10496598.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Apr;12(2):122-6 [15167049.001]
  • [Cites] Cancer Detect Prev. 1994;18(4):241-52 [7982234.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):386-95 [10716152.001]
  • [Cites] Acta Otorrinolaringol Esp. 1999 Nov-Dec;50(8):667-70 [10619908.001]
  • [Cites] Drug Saf. 2000 Aug;23(2):101-13 [10945373.001]
  • [Cites] Pathol Int. 2004 Sep;54(9):649-58 [15363032.001]
  • [Cites] QJM. 2005 Mar;98(3):205-14 [15728402.001]
  • (PMID = 16596381.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


91. Haque AU, Moatasim A: Giant cell tumor of bone: a neoplasm or a reactive condition? Int J Clin Exp Pathol; 2008;1(6):489-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of bone: a neoplasm or a reactive condition?
  • Giant cell tumor of bone (GCTB) is a benign but locally aggressive bone tumor of young adults.
  • Microscopically areas of frank hemorrhage, numerous multinucleated giant cells and spindly stromal cells are present.
  • While giant cells and stromal cells have been extensively studied, little attention has been paid to the overwhelming hemorrhagic component.
  • If examined carefully intact and partially degenerated red blood cells are almost invariably seen in many giant cells as well as in the stroma.
  • While hemorrhage in many patients may be resolved without leaving any trace over time, in some it gives rise to giant cell formation, and in others it may lead to proliferation of fibroblasts and histiocytes.
  • Malignancy usually does not occur in GCTB and when discover, it usually represents primary bone sarcomas missed at original diagnosis.
  • Aneurysmal bone cyst (ABC) shares many features with GCTB.
  • There had been unique karyotypic changes in some aneurysmal bone cysts making it distinct from GCTB.
  • However these changes may be in the endothelial cells which are quite different from stromal or giant cells.
  • Enhanced telomerase activity and karyotypic aberrations may be necessary for rapid division of the nuclei of the giant cells in order to be able to deal with significant in situ intraosseous hemorrhage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):375-8 [12451570.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Histol Histopathol. 2001 Jan;16(1):297-307 [11193206.001]
  • [Cites] J Bone Miner Res. 2000 Apr;15(4):640-9 [10780856.001]
  • [Cites] J Postgrad Med. 1995 Jul-Sep;41(3):83-4 [10707722.001]
  • [Cites] Pathology. 1999 Nov;31(4):373-8 [10643009.001]
  • [Cites] Endocrinology. 1994 Jun;134(6):2416-23 [8194468.001]
  • [Cites] J Clin Invest. 1994 May;93(5):1959-67 [8182127.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1094-9 [7850706.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):465-71 [7526033.001]
  • [Cites] Nihon Seikeigeka Gakkai Zasshi. 1994 May;68(5):407-14 [7914219.001]
  • [Cites] Am J Pathol. 1994 Oct;145(4):856-67 [7943176.001]
  • [Cites] Br J Oral Maxillofac Surg. 1993 Apr;31(2):89-94 [8471587.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(5):301-3 [8440744.001]
  • [Cites] J Cell Sci. 1992 Mar;101 ( Pt 3):681-6 [1522150.001]
  • [Cites] Lab Invest. 1992 Aug;67(2):166-74 [1501443.001]
  • [Cites] J Clin Pathol. 1992 May;45(5):398-404 [1597517.001]
  • [Cites] Br J Cancer. 1992 Apr;65(4):523-6 [1562461.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):66-80 [1555533.001]
  • [Cites] Endocrinology. 1991 May;128(5):2324-35 [1850350.001]
  • [Cites] Endocrinol Jpn. 1990 Oct;37(5):741-7 [2086204.001]
  • [Cites] Acta Cytol. 1990 Nov-Dec;34(6):863-7 [2256421.001]
  • [Cites] Endocrinology. 1989 Jul;125(1):20-7 [2544401.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):59-75 [3006962.001]
  • [Cites] Nature. 1961 Apr 29;190:459-60 [13777407.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4353-63 [9751519.001]
  • [Cites] J Cell Biochem. 1998 Jul 1;70(1):121-9 [9632113.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Dec;55(12 Suppl 5):38-45 [9393425.001]
  • [Cites] J Pathol. 1985 Apr;145(4):297-305 [2987469.001]
  • [Cites] J Pathol. 1987 Oct;153(2):121-6 [2961857.001]
  • [Cites] Cell Tissue Res. 1985;241(3):671-5 [2992797.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1139-45 [2457425.001]
  • [Cites] Recent Prog Horm Res. 1989;45:507-27; discussion 527-31 [2682847.001]
  • [Cites] Endocrinology. 1988 Apr;122(4):1373-82 [3345718.001]
  • [Cites] Veroff Pathol. 1984;122:1-195 [6091360.001]
  • [Cites] Cancer Res. 1987 Aug 1;47(15):4141-5 [3300960.001]
  • [Cites] J Pathol. 1984 Dec;144(4):281-94 [6520652.001]
  • [Cites] J Cell Sci. 1984 Aug;70:61-71 [6501437.001]
  • [Cites] J Interferon Res. 1987 Oct;7(5):619-26 [3479501.001]
  • [Cites] J Oral Maxillofac Surg. 1986 Sep;44(9):708-13 [3462363.001]
  • [Cites] Endocrinology. 1986 Feb;118(2):824-8 [3455914.001]
  • [Cites] Am J Pathol. 1986 Feb;122(2):363-78 [3946557.001]
  • [Cites] J Bone Joint Surg Am. 1990 Feb;72(2):252-8 [1968067.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7260-4 [2169622.001]
  • [Cites] Endocrinology. 1990 Jun;126(6):3153-8 [2161750.001]
  • [Cites] Endocrinology. 1990 May;126(5):2733-41 [2184023.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2697-703 [2340469.001]
  • [Cites] Science. 1980 May 2;208(4443):516-8 [6154315.001]
  • [Cites] Int J Oral Surg. 1984 Apr;13(2):92-100 [6430822.001]
  • [Cites] Pathol Res Pract. 1984 May;178(5):431-40 [6462948.001]
  • [Cites] Calcif Tissue Int. 1980;31(1):29-34 [6770971.001]
  • [Cites] Pathol Res Pract. 1999;195(11):753-7 [10605695.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2896-902 [17653593.001]
  • [Cites] Bosn J Basic Med Sci. 2007 Feb;7(1):58-65 [17489771.001]
  • [Cites] Fetal Pediatr Pathol. 2006 Sep-Oct;25(5):241-8 [17438664.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):484-9 [17013643.001]
  • [Cites] J Bone Miner Res. 2006 Sep;21(9):1339-49 [16939392.001]
  • [Cites] Ultrastruct Pathol. 2006 May-Jun;30(3):151-8 [16825116.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):589-94 [16465417.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):945-54 [16153456.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:116-22 [16131879.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):117-28 [15972958.001]
  • [Cites] Cancer Genet Cytogenet. 2005 May;159(1):32-6 [15860354.001]
  • [Cites] J Assoc Physicians India. 2004 Jul;52:585-6 [15645990.001]
  • [Cites] J Orthop Res. 2005 Jan;23(1):203-9 [15607894.001]
  • [Cites] Clin Orthop Relat Res. 1997 May;(338):205-14 [9170381.001]
  • [Cites] Ann Rheum Dis. 1996 Jun;55(6):388-95 [8694579.001]
  • [Cites] Cancer Genet Cytogenet. 1996 May;88(1):35-8 [8630976.001]
  • [Cites] Bone. 1995 Aug;17(2 Suppl):87S-91S [8579904.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Clin Orthop Relat Res. 1976 Oct;(120):201-31 [975659.001]
  • [Cites] N Engl J Med. 1974 Nov 14;291(20):1041-6 [4413338.001]
  • [Cites] Science. 1973 May 25;180(4088):875 [4706681.001]
  • [Cites] Science. 1975 Nov 21;190(4216):784-5 [1105786.001]
  • [Cites] J Exp Med. 1975 Sep 1;142(3):651-63 [1100763.001]
  • [Cites] J Bone Joint Surg Am. 1976 Jul;58(5):612-8 [932060.001]
  • [Cites] Nature. 1975 Nov 27;258(5533):325-7 [1196357.001]
  • [Cites] J Endocrinol. 1969 Nov;45(3):387-400 [5358264.001]
  • [Cites] J Pathol Bacteriol. 1966 Jul;92(1):163-7 [5956253.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Sep;8(5):316-21 [15480872.001]
  • [Cites] Hand Clin. 2004 Aug;20(3):269-81, vi [15275686.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):983-93 [14608531.001]
  • [Cites] Diagn Cytopathol. 2004 Jan;30(1):14-8 [14696139.001]
  • [Cites] Pathobiology. 2002-2003;70(6):333-42 [12865629.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • (PMID = 18787633.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480584
  • [Keywords] NOTNLM ; Giant cell tumor / aneurysmal bone cyst / bone / bone matrix / hemorrhage / osteoclast / osteoclastoma / telomerase
  •  go-up   go-down


92. Rabinovich A, Mak IW, Cowan RW, Turcotte RE, Colterjohn N, Singh G, Ghert M: Matrix Metalloproteinase Activity in the Stromal Cell of Giant Cell Tumor of Bone. Open Bone J; 2009;1:46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix Metalloproteinase Activity in the Stromal Cell of Giant Cell Tumor of Bone.
  • Giant cell tumor of bone (GCT) is a destructive and potentially metastatic bone tumour in which the characteristic giant cells have classically been considered the culprits in bone destruction.
  • However, the neoplastic element of the tumour consists of propagative osteoblast-like stromal cells that may play a role in bone resorption.
  • The objectives of this study were to determine the expression and activity of the gelatinases, matrix metalloproteinase (MMP)-2 and -9, in GCT stromal cells, and to determine if these cells have bone-resorbing capabilities.
  • We performed immunohistochemistry on clinical specimens, and real-time polymerase chain reaction (PCR) and zymography on cell lysates and conditioned media from cultured clinical GCT specimens in order to evaluate the expression and activity of MMP-2 and-9 in GCT stromal cells.
  • These cells may therefore play a role in bone destruction in GCT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22287999.001).
  • [Journal-full-title] The Open bone journal
  • [ISO-abbreviation] Open Bone J
  • [Language] ENG
  • [Grant] None / None / / 93755; United States / PHS HHS / / 93755
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] Netherlands
  •  go-up   go-down


93. Slesarenko YA, Sampson SP, Gould ES: Giant cell tumour of the distal phalanx of the hand. Hand Surg; 2005;10(2-3):289-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumour of the distal phalanx of the hand.
  • Giant cell tumour of bone in the phalanx of the hand is extremely rare.
  • A case of giant cell tumour of distal phalanx treated with a ray amputation is presented.
  • [MeSH-major] Bone Neoplasms / surgery. Fingers. Giant Cell Tumor of Bone / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16568530.001).
  • [ISSN] 0218-8104
  • [Journal-full-title] Hand surgery : an international journal devoted to hand and upper limb surgery and related research : journal of the Asia-Pacific Federation of Societies for Surgery of the Hand
  • [ISO-abbreviation] Hand Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


94. Miszczyk L, Spindel J, Blamek S, Syguła M, Koczy B: [Lung dissemination of giant cell tumor of femur. The case report]. Przegl Lek; 2005;62(9):944-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung dissemination of giant cell tumor of femur. The case report].
  • The case of 32 years old patient suffering for giant cell bone tumor of left femur was reported.
  • After surgery (curettage and filling of tumor bed with bone cement followed by arthroplasty), a dissemination to lungs was found.
  • [MeSH-major] Bone Neoplasms / pathology. Femur / pathology. Giant Cell Tumors / secondary. Lung Neoplasms / secondary
  • [MeSH-minor] Adult. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / radiography. Giant Cell Tumor of Bone / radiotherapy. Humans. Male. Neoplasms, Second Primary / radiography. Neoplasms, Second Primary / radiotherapy. Radiotherapy Dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541735.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


95. Kyrgidis A, Toulis K: Safety and efficacy of denosumab in giant-cell tumour of bone. Lancet Oncol; 2010 Jun;11(6):513-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of denosumab in giant-cell tumour of bone.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Giant Cell Tumor of Bone / drug therapy. RANK Ligand / therapeutic use

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2010 Sep;11(9):815 [20816372.001]
  • [CommentOn] Lancet Oncol. 2010 Mar;11(3):275-80 [20149736.001]
  • (PMID = 20522379.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / RANK Ligand; 4EQZ6YO2HI / Denosumab
  •  go-up   go-down


96. Suzuki Y, Nishida Y, Yamada Y, Tsukushi S, Sugiura H, Nakashima H, Ishiguro N: Re-operation results in osteoarthritic change of knee joints in patients with giant cell tumor of bone. Knee; 2007 Oct;14(5):369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re-operation results in osteoarthritic change of knee joints in patients with giant cell tumor of bone.
  • Giant cell tumor of bone occasionally results in secondary osteoarthritic changes in adjacent joints.
  • The purpose of this study was to determine the factors associated with the development of degenerative arthritis in surgically treated patients with giant cell tumor of the distal femur or proximal tibia and the effect of residual subchondral bone thickness on the location of recurrent giant cell tumor.
  • We retrospectively studied 30 patients with giant cell tumor of bone arising around the knee joint treated with intralesional curettage, high-speed burring, and electrocauterization, followed by filling with polymethylmethacrylate or autogenous bone graft.
  • There was no significant difference in factors of age, gender, tumor location, residual thickness of subchondral bone, or Campanacci grade correlated with the recurrence.
  • Less than 5 mm of residual thickness of subchondral bone was correlated with recurrence on the articular side (p=0.038).
  • Less residual thickness of subchondral bone tended to be associated with secondary osteoarthritis (p=0.068).
  • These data support the contention that the residual thickness of subchondral bone could be a factor predicting the location of recurrence, and operative procedure to avoid re-operation might be critical to preserve knee function.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Neoplasm Recurrence, Local / surgery. Osteoarthritis, Knee / etiology. Osteoarthritis, Knee / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Cements / therapeutic use. Female. Femoral Fractures / surgery. Femur / pathology. Femur / surgery. Follow-Up Studies. Humans. Male. Middle Aged. Polymethyl Methacrylate / therapeutic use. Postoperative Complications. Reoperation. Retrospective Studies. Tibia / pathology. Tibia / surgery. Tibial Fractures / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601737.001).
  • [ISSN] 0968-0160
  • [Journal-full-title] The Knee
  • [ISO-abbreviation] Knee
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Cements; 9011-14-7 / Polymethyl Methacrylate
  •  go-up   go-down


97. Trabelsi A, Hammedi F, Slama A, Abdelkarim SB, Beïzig N, Khochtali H, Taher YM, Korbi S: Giant cell tumor of soft tissue of neck: a case report. N Am J Med Sci; 2009 Nov;1(6):319-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of soft tissue of neck: a case report.
  • CONTEXT: Giant cell tumor of soft tissue is a rare primary soft tissue tumor with low malignant potential.
  • It is clinically and pathologically similar to the giant cell tumor of the bone.
  • Computed tomography suggested a neurogenic tumor, but the diagnosis of giant cell tumor was confirmed after detailed pathological examination.
  • The patient remains disease free five months after diagnosis.
  • CONCLUSION: It is important to recognize this pathological entity in order to avoid misdiagnosis with other fibrous tumors associated with giant cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1972 May;107(1):27-39 [4262633.001]
  • [Cites] Mod Pathol. 1999 Sep;12(9):894-902 [10496598.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):386-95 [10716152.001]
  • [Cites] Korean J Radiol. 2008 Sep-Oct;9(5):462-5 [18838857.001]
  • [Cites] Clin Radiol. 2008 Jan;63(1):101-7 [18068797.001]
  • [Cites] Pathol Int. 2001 Jan;51(1):60-3 [11148467.001]
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):100-5 [12004357.001]
  • [Cites] Skeletal Radiol. 2004 May;33(5):295-9 [14997349.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1175-6 [10935663.001]
  • (PMID = 22666716.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3364635
  • [Keywords] NOTNLM ; Giant cell tumor / histopathology / soft tissue neck
  •  go-up   go-down


98. Li HT, Wang WJ, Zhu GD, Lai RQ: [Giant cell tumor of temporal bone and mandibular condyle: a case report]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2010 Aug;28(4):450-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumor of temporal bone and mandibular condyle: a case report].
  • Giant cell tumor of bone (GCTB) seldom occurs in the head or face.
  • This article reported a case that GCTB occurred simultaneously in the temporal bone and mandibular condyle, and analyzed their clinical and pathological features.
  • [MeSH-major] Bone Neoplasms. Giant Cell Tumor of Bone. Mandibular Condyle / pathology. Mandibular Neoplasms. Temporal Bone / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20848946.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


99. Emanuel PO, Shim H, Phelps RG: Poorly differentiated squamous cell carcinoma with osteoclastic giant-cell-like proliferation. J Cutan Pathol; 2007 Dec;34(12):930-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated squamous cell carcinoma with osteoclastic giant-cell-like proliferation.
  • Although osteoclast giant-cell-like proliferations have been reported in a diverse range of human malignancies, to the best of our knowledge, they have never been described in cutaneous squamous cell carcinoma (SCC).
  • Histologically, osteoclastic giant cell tumors within extraosseous malignancy resemble their bony and soft tissue counterparts, with round to spindle-shaped cells admixed with osteoclast-like multinucleate cells.
  • These cells should be distinguished from sarcomatoid differentiation within a carcinoma; they have a benign morphology with a low nuclear to cytoplasmic ratio, minimal pleomorphism/mitoses and negative immunohistochemistry for cytokeratin.
  • The authors report the rare occurrence of osteoclast-like giant cells (OGCs) and accompanying epithelioid histiocytes lacking overtly malignant features in association with a poorly differentiated SCC occurring on sun-damaged skin.
  • The histological differential diagnosis and the origin of the proliferation are discussed in this article.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Giant Cells / pathology. Lip / pathology. Osteoclasts / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biomarkers, Tumor / analysis. Cell Proliferation. Diagnosis, Differential. Giant Cell Tumor of Bone / pathology. Giant Cell Tumors / pathology. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18001416.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human
  •  go-up   go-down


100. Li D, Zhang Z, Huang M: [Prosthesis replacement of proximal humerus after resection of malignant tumor]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct;20(10):996-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prosthesis replacement of proximal humerus after resection of malignant tumor].
  • OBJECTIVE: To study the operative effect and complication of the prosthesis replacement of the proximal humerus with malignant tumor.
  • METHODS: From October 1998 to August 2003, the prosthesis replacement was performed to treat the proximal femur with malignant tumor in 4 patients, including 2 patients with osteosarcoma (Enneking staging, I A) and 2 patients with giant cell tumor of the bone (II A, II B).
  • By the International Society of Limb Salvage (ISOLS) criterion, the 2 cases of osteosarcoma were preoperatively scored as 4 and 5 points, and 2 cases of giant cell tumor of the bone were scored as 9 and 11 points.
  • By the criterion formulated by the ISOLS, the postoperative score for assessing the 2 patients with osteosarcoma was increased by 16 points when compared with the preoperative score; the score for the 2 patients with giant cell tumor of the bone was increased by 9.5 points.
  • CONCLUSION: The prosthesis replacement to treat the malignant tumor of the proximal humerus is the good method of choice and has a good therapeutic result; however, there are more complications and so the method should be cautiously employed in the clinical practice.
  • [MeSH-major] Arthroplasty, Replacement. Bone Neoplasms / surgery. Humerus
  • [MeSH-minor] Adult. Artificial Limbs. Female. Follow-Up Studies. Giant Cell Tumors / surgery. Humans. Male. Middle Aged. Osteosarcoma / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140072.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement